Be A Freedom Fighter · Bill Library

HR 10857 — To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes.

Freedom score: -3 (scale −10 to +10)

Sponsor: Rep. Auchincloss, Jake [D-MA-4] · Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (2026-10-22)

Full text on GovInfo (introduced version) · Congress.gov · ← Bill Library index

Findings — 114 highlighted provisions

Each item below is one provision documented in the findings file. The same provision is highlighted in the full text underneath, with its section citation and criterion. Everything else on this page is plain, unreviewed bill text.

  1. Sec. 101–107 — 201–205, 301–307, 401–403, and 501 See in text ↓
  2. Sec. 401 — consists of nonoperative findings/purpose and is not independently scored. Each item below identifies its affected parties and enforcement mechanism. Where a provision only directs an agency to study, issue guidance, or report, no new private penalty is created by that provision. Existing FDA approval, inspection, human-subject protections, Medicare payment, and federal award conditions apply where indicated See in text ↓
  3. Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment See in text ↓
  4. Sec. 107(a)(1)(A)–(B), (a)(2) · Individual Rights — Requires CMS within 18 months to clarify Medicare routine-cost coverage for qualifying point-of-care trials, including digital/remote care, align quality data standards, and address use of such evidence in national coverage decisions. Affected: Medicare beneficiaries, providers, sponsors. Mechanism: existing Medicare coverage determinations; no standalone fine See in text ↓
  5. Sec. 107(b)–(c) · Individual Rights — Requires HHS within one year to make rules for fair compensation of clinical-trial participants and participating sites, taking account of research risks, burdens and undue influence. Affected: participants, investigators and sponsors. Mechanism: future rules and existing research oversight See in text ↓
  6. Sec. 106(b)(2) · Property Rights — Requires IRB-disclosure rules to preserve confidential commercial information and trade secrets while publishing decision summaries. Affected: sponsors and research institutions. Mechanism: HHS/FDA/NIH rulemaking and existing confidentiality protections See in text ↓
  7. Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions See in text ↓
  8. Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines See in text ↓
  9. Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration See in text ↓
  10. Sec. 101(a), new §499B(h)–(i) · Economic Freedom — Requires FDA external engagement and guidance within 18 months on decentralized trials, central IRBs, electronic consent, monitoring and real-world evidence. Mechanism: guidance and existing FDA authority See in text ↓
  11. Sec. 101(a), new §499B(j)(1)–(2) · Economic Freedom — Requires annual public/congressional progress reports and evaluations after three and five years. Mechanism: agency reporting See in text ↓
  12. Sec. 101(a), new §499B(l); Sec. 101(b)(1)–(2) · Economic Freedom — Authorizes $500 million annually FY2027–2031 for the initiative, and revises FDA Innovation Account transfers to $20m/$60m/$70m/$75m/$70m in FY2027–2031 and related appropriation authorization. Distinguish authorized appropriations from mandated transfers. Affected: federal programs and award recipients See in text ↓
  13. Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions See in text ↓
  14. Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors See in text ↓
  15. Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting See in text ↓
  16. Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation See in text ↓
  17. Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight See in text ↓
  18. Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process See in text ↓
  19. Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation See in text ↓
  20. Sec. 106(a)(1)–(4) · Economic Freedom — Requires one IRB for covered multi-institutional clinical investigations, allowing alternatives when the sponsor demonstrates necessity; FDA must make implementing rules within one year. Affected: sponsors and IRBs. Mechanism: existing human-subjects/FDA compliance See in text ↓
  21. Sec. 106(c) · Economic Freedom — Expands FDA bioresearch monitoring through user-fee performance commitments. Mechanism: existing FDA inspection/oversight See in text ↓
  22. Sec. 101(a), new §499B(c)(6)(B)–(C), (i)(1)–(3) · Privacy and Due Process — Requires coordination on electronic consent, interoperable clinical/real-world data, confidentiality protections, monitoring and central IRB reliance. Mechanism: program standards and FDA guidance See in text ↓
  23. Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law See in text ↓
  24. Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards See in text ↓
  25. Sec. 105(e) · Privacy and Due Process — Permits CMS linkage/tokenization capabilities for trial data only in compliance with HIPAA, the Privacy Act and 42 CFR part 2. Affected: patient data holders and participants. Mechanism: incorporated privacy statutes See in text ↓
  26. Sec. 105(f) · Privacy and Due Process — Directs federal assessment of real-world data and AI/digital tools for product-efficacy, label-expansion and regulatory decisionmaking. Mechanism: agency assessment; no new individual disclosure penalty See in text ↓
  27. Sec. 106(a)(1)–(3) · Privacy and Due Process — Centralizes IRB review with limited alternatives; changes review procedure rather than eliminating human-subject protections. Mechanism: FDA rulemaking and IRB oversight See in text ↓
  28. Sec. 106(b)(1)–(3) · Privacy and Due Process — Requires rules within one year to publish IRB deliberation summaries and decision bases, while protecting health information, trade secrets and confidential business information, preferably through ClinicalTrials.gov. Mechanism: agency rulemaking See in text ↓
  29. Sec. 101(a), new §499B(a)–(b) · Government Power — Establishes an FDA Center for Clinical Trial Innovation and a Cures in Care Initiative, with HHS, FDA and NIH coordination. Mechanism: statutory administrative duties See in text ↓
  30. Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers See in text ↓
  31. Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication See in text ↓
  32. Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA See in text ↓
  33. Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope See in text ↓
  34. Sec. 105(a)–(f); Sec. 106(a)–(c); Sec. 107(a)–(c) · Government Power — Assigns interagency data standards, FDA IRB rulemaking/monitoring, and CMS trial coverage and participant-payment rules See in text ↓
  35. Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation See in text ↓
  36. Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process See in text ↓
  37. Sec. 201(b)(2), (c)(1)(B)–(C) · Property Rights — Requires consideration of intellectual-property/proprietary protections as incentives for sponsors to share preclinical-methodology data. Affected: drug sponsors and technology developers. Mechanism: future FDA validation policy; no immediate compulsory patent transfer See in text ↓
  38. Sec. 201(a)(1)–(2) · Economic Freedom — Requires FDA guidance/evidence frameworks within two years on in-vitro, in-silico and other new methodologies for preclinical studies and IND submissions. Mechanism: future guidance and existing drug approval See in text ↓
  39. Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender See in text ↓
  40. Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules See in text ↓
  41. Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules See in text ↓
  42. Sec. 202(e)(1)–(3) · Economic Freedom — Defines higher-risk trials by genome modification, replication, irreversible biological effects, immune risk, prior clinical holds or unreasonable significant harm; lower-risk includes minimal-harm, exploratory/subtherapeutic or investigator-initiated trials. Mechanism: eligibility classification, not a new penalty See in text ↓
  43. Sec. 203(a), amended FDCA §803(b)(2), (d)(1)–(2) · Economic Freedom — Adds international Good Clinical Practice recognition and FDA global coordination for foreign trials and real-world data. Mechanism: FDA inspection/approval See in text ↓
  44. Sec. 203(b), new FDCA §704(i)(1)–(2) · Economic Freedom — Requires inspected clinical establishments to pre-certify GCP compliance; requires verification for covered biotechnology companies of concern and authorizes inspection-cost fees. Affected: site owners/operators/agents. Mechanism: FDA inspection, fees and approval decisions See in text ↓
  45. Sec. 203(c)(1)–(2) · Economic Freedom — Permits FDA to demand source data, audit trails, translated consent records and sample chains of custody for foreign phase 1–2 studies, and reject data for noncompliance. Affected: sponsors/investigators. Mechanism: FDA refusal to accept clinical data See in text ↓
  46. Sec. 203(d) · Economic Freedom — Requires FDA within 18 months to clarify consequences for delaying/denying inspections. Mechanism: guidance and existing inspection law See in text ↓
  47. Sec. 204(a)–(b) · Economic Freedom — Requires U.S.-enrolled patients in specified pivotal studies and restricts approvals relying only on foreign clinical data, subject to statutory exceptions/waivers where domestic studies are unavailable, impracticable, or emergency conditions justify. Affected: drug and biologic sponsors. Mechanism: FDA marketing-application review See in text ↓
  48. Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards See in text ↓
  49. Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations See in text ↓
  50. Sec. 201(c)(1)(B) · Privacy and Due Process — Includes data-security and proprietary safeguards in the new-methodology validation policy. Mechanism: FDA guidance See in text ↓
  51. Sec. 202(b)(2)–(5) · Privacy and Due Process — Provides qualification and safety review for delegated third-party trial assessments; high-risk categories are not automatically eligible for expedited review. Mechanism: FDA/IRB controls See in text ↓
  52. Sec. 203(b), new FDCA §704(i)(1)–(2) · Privacy and Due Process — Imposes pre-certification and federal verification/inspection of specified clinical sites, with inspection cost fees. Mechanism: FDA inspection authority See in text ↓
  53. Sec. 203(c)(1)(A)–(D), (c)(2) · Privacy and Due Process — Authorizes compelled foreign patient-level source data, audit trails, translated informed-consent records, specimen custody and other documentation; FDA may reject evidence if the sponsor refuses. Affected: foreign trial participants and sponsors. Mechanism: evidence exclusion at FDA See in text ↓
  54. Sec. 204(b) · Privacy and Due Process — Gives FDA waiver/exception discretion for U.S. enrollment and foreign-data requirements, including public-health emergencies. Mechanism: FDA application decisions See in text ↓
  55. Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties See in text ↓
  56. Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines See in text ↓
  57. Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers See in text ↓
  58. Sec. 204(a)–(b) · Government Power — Adds FDA authority to enforce domestic-patient participation and grant defined waivers See in text ↓
  59. Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions See in text ↓
  60. Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight See in text ↓
  61. Sec. 304(a)(4)–(6), amended PHSA §351(k)(4), amended PHSA §351(k)(6) · Property Rights — Revises biosimilar interchangeability and preserves qualifying unexpired first-interchangeable exclusivity during transition; affects biologic applicants and exclusivity holders. Mechanism: FDA biologics licensure See in text ↓
  62. Sec. 305, new PHSA §351(o)(1)(A)(i)–(iv), (B) · Property Rights — Requires specified biologic applications relying on covered third-party investigations to certify each covered patent as unfiled, expired, expiring on a stated date, or invalid/noninfringed, and to distinguish irrelevant method-of-use patents. Affected: applicants and patent holders. Mechanism: FDA application completeness and existing patent procedures; no new infringement damages specified See in text ↓
  63. Sec. 305, new §351(o)(2)(A)–(B) · Property Rights — Limits certifications to defined covered investigations and patents, including third-party studies used without a right of reference. Mechanism: statutory application scope See in text ↓
  64. Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval See in text ↓
  65. Sec. 301(b) · Economic Freedom — Authorizes $500 million annually FY2027–2031 for process improvements, available until expended; not automatically appropriated See in text ↓
  66. Sec. 302(a), amended FDCA §809(a) · Economic Freedom — Broadens reliance on qualifying foreign government GMP inspections and related medical-product inspection recognition. Affected: manufacturers. Mechanism: FDA inspection law See in text ↓
  67. Sec. 302(b), amended FDCA §803(b)(3) · Economic Freedom — Requires bioresearch monitoring to seek reciprocal inspection reliance, reduced duplicate U.S. inspections and risk-based oversight. Mechanism: FDA regulatory collaboration See in text ↓
  68. Sec. 303(a)–(c) · Economic Freedom — Requires FDA to review the competitive-generic-therapy pathway within 12 months, report recommendations and begin implementing them within six months after submission, consulting stakeholders. Mechanism: FDA program implementation; no automatic product approval See in text ↓
  69. Sec. 304(a)(1)–(6) · Economic Freedom — Removes the separate statutory interchangeability distinction and deems biosimilars interchangeable after a 60-day transition, subject to preserved exclusivity; revises related statutory language. Mechanism: FDA biologics licensing and substitution law See in text ↓
  70. Sec. 304(b), amended FDCA §505B(m) · Economic Freedom — Adjusts pediatric-assessment treatment of biosimilars based on reference-product indications and available formulations. Mechanism: existing pediatric drug/biologics review See in text ↓
  71. Sec. 304(c)(1)–(3), (d)(1)–(2) · Economic Freedom — Requires biosimilar/interchangeability guidance updates within 18 months and follow-up after comments; preserves biosimilarity licensing standard and FDA evidence authority. Mechanism: FDA guidance/licensure See in text ↓
  72. Sec. 305, new §351(o)(1)–(2) · Economic Freedom — Adds patent certifications and method-of-use statements to qualifying biologics applications. Mechanism: FDA application review See in text ↓
  73. Sec. 301(a)(6)–(7) · Privacy and Due Process — Requires clarification of confidential-information redaction and procedures for publishing FDA complete response letters and investigational/premarket application materials, including possible automation and pilot disclosure. Affected: applicants and public. Mechanism: FDA disclosure procedures subject to existing confidentiality law See in text ↓
  74. Sec. 305, new §351(o)(1)(A)–(B) · Privacy and Due Process — Requires applicants to make formal patent-status and noninfringement assertions; their legal significance depends on incorporated biologics and patent procedures. Mechanism: FDA application requirements See in text ↓
  75. Sec. 306(1)–(5) · Privacy and Due Process — Requires GAO review within three years of FDA process reforms, user-fee pilots and rare-disease effects; no individual hearing or penalty See in text ↓
  76. Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031 See in text ↓
  77. Sec. 302(a)–(b) · Government Power — Expands foreign inspection recognition and international bioresearch monitoring coordination See in text ↓
  78. Sec. 303(a)–(c) · Government Power — Requires FDA competitive-generic pathway study and implementation steps See in text ↓
  79. Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance See in text ↓
  80. Sec. 305, new §351(o)(1)–(2) · Government Power — Adds patent-information certification requirements to covered biologic applications See in text ↓
  81. Sec. 306(1)–(5) · Government Power — Requires GAO report within three years See in text ↓
  82. Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties See in text ↓
  83. Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section See in text ↓
  84. Sec. 403(b)(2)(C), (h)(1)–(2) · Property Rights — Encourages voluntary sponsor labeling supplements and preserves existing drug approval status except authorized label updates; does not independently transfer patent rights. Mechanism: FDA labeling law See in text ↓
  85. Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration See in text ↓
  86. Sec. 402(c)(1)–(2) · Economic Freedom — Requires FY2027–2031 transfers of such sums as necessary from specified existing FDA, interagency and ARPA-H-related funds, plus presidential budget identification. Mechanism: agency fiscal transfers, not an unrestricted new appropriation See in text ↓
  87. Sec. 403(a), (b)(1)–(2) · Economic Freedom — Requires a genomic-exclusion labeling assessment program within 12 months, identification of eligible oncology drugs and evidence channels, standardized language, voluntary supplements and agency updates where supported. Mechanism: FDA labeling process See in text ↓
  88. Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers See in text ↓
  89. Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections See in text ↓
  90. Sec. 403(h)(1)–(2), (i)(1)–(3) · Privacy and Due Process — Preserves other FDA labeling authority and existing approvals except label updates; defines actionable genetic alteration, targeted therapy and genomic exclusion. Mechanism: existing FDA procedures See in text ↓
  91. Sec. 401(a)–(b) · Government Power — Legislative findings/purpose only; no independently operative obligation See in text ↓
  92. Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031 See in text ↓
  93. Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers See in text ↓
  94. Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment See in text ↓
  95. Sec. 501(a), new §404P(b)(1)–(2) · Property Rights — Transfers existing All of Us program authorities, appropriations, personnel, data, specimens and infrastructure to the new federal Biobank; no compulsory private property taking is specified. Mechanism: NIH internal transition and existing award law See in text ↓
  96. Sec. 501(a), new §404P(d)(1), new §404P(d)(4), new §404P(d)(11) · Economic Freedom — Requires nationwide corporate/nonprofit awards and data-sharing agreements and permits public/private financing to collect/analyze specimens and clinical data. Affected: research institutions and contractors. Mechanism: federal contracts and awards See in text ↓
  97. Sec. 501(a), new §404P(i) · Economic Freedom — Authorizes $500 million for FY2027 and each subsequent fiscal year, available until expended; no statutory end date. This is an authorization, not an automatic appropriation See in text ↓
  98. Sec. 501(b) · Economic Freedom — Requires NIH within 180 days to submit a five-fiscal-year scientific, infrastructure, partnership-financing and budget roadmap. Mechanism: congressional oversight See in text ↓
  99. Sec. 501(a), new §404P(d)(1)–(2) · Privacy and Due Process — Authorizes collection/storage of biospecimens, longitudinal molecular/clinical data and electronic health records, with a target cohort of at least 3% of the population. Mechanism: NIH agreements and existing consent/privacy law See in text ↓
  100. Sec. 501(a), new §404P(d)(3)–(4) · Privacy and Due Process — Requires mutually agreed tribal participation and data-sharing agreements with private/nonprofit partners to recruit, enroll and obtain informed consent. Mechanism: consultation and contractual oversight See in text ↓
  101. Sec. 501(a), new §404P(d)(5)–(7) · Privacy and Due Process — Requires trial recruitment using Biobank data, sharing deidentified data with all registered researchers and incorporating NIH/VA datasets including All of Us and Million Veteran Program. Mechanism: NIH researcher registration, agreements and privacy law See in text ↓
  102. Sec. 501(a), new §404P(d)(8)–(10), (f) · Privacy and Due Process — Authorizes integrated genomic/proteomic/metabolomic and health-record data, repeat sampling, continuous data integration, federated AI-ready systems and linked environmental/life-course data. Mechanism: NIH program controls; reidentification risk and specific access safeguards depend on implementation See in text ↓
  103. Sec. 501(a), new §404P(g)(1)(A)–(B), (g)(2) · Privacy and Due Process — Requires informed consent or authorized-representative permission and at least existing federal/state privacy protections for biospecimens and associated clinical/demographic data. Mechanism: incorporated human-subject/privacy laws and NIH oversight; no independent new statutory damages remedy See in text ↓
  104. Sec. 501(a), new §404P(a)–(c) · Government Power — Creates the American Frontier Biobank under NIH, transfers All of Us authorities, budget, staff and infrastructure within six months, and creates an NIH-appointed Administrator See in text ↓
  105. Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board See in text ↓
  106. Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives See in text ↓
  107. Sec. 501(a), new §404P(f)–(g) · Government Power — Permits multimodal data linkage and requires consent and privacy compliance See in text ↓
  108. Sec. 501(a), new §404P(h)–(i) · Government Power — Requires annual congressional notification beginning one year after enactment and authorizes $500 million in FY2027 and every later fiscal year, without an express sunset See in text ↓
  109. Sec. 501(b) · Government Power — Requires a five-year implementation and financing roadmap within 180 days See in text ↓
  110. Sec. 203(c)(2) · Government Power — and may charge inspection fees See in text ↓
  111. Sec. 203(b) · Government Power — most other agency study, guidance and grant provisions create no new standalone criminal penalty. Appropriation authorizations are not assumed to have been funded. The five titles contain no general sunset; the FY2027–2031 limits on some authorities do not sunset the permanent Biobank authorization See in text ↓
  112. Sec. 501(a), Sec. 404P(i) · Government Power — most other agency study, guidance and grant provisions create no new standalone criminal penalty. Appropriation authorizations are not assumed to have been funded. The five titles contain no general sunset; the FY2027–2031 limits on some authorities do not sunset the permanent Biobank authorization See in text ↓
  113. Sec. 203(c)(1)–(2) · Government Power — alongside long-term longitudinal genomic/clinical data integration See in text ↓
  114. Sec. 501(a), Sec. 404P(d)(5)–(10) · Government Power — notwithstanding explicit consent safeguards See in text ↓
  115. Sec. 404P(g) · Government Power — Consequently Direction changes from −2 to −3, and Impact remains 18. This is a rubric judgment subject to human review, not a statement that the biobank compels public participation Provision location not found in introduced text — see finding.

Full text (introduced version)

359 of 379 text blocks highlighted. Source: GovInfo, fetched cached.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 10857 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 10857 To amend the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES October 22, 2026 Mr. Auchincloss (for himself and Mr. Griffith) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To amend the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE; TABLE OF CONTENTS.

(a) Short Title.--This Act may be cited as the ``Faster Clinical Trials Act''.
(b) Table of Contents.--The table of contents for this Act is as follows: Sec. 1. Short title; table of contents. TITLE I--EMBEDDING CLINICAL STUDIES IN ROUTINE HEALTH CARE Sec. 101. Cures in Care Initiative. Sec. 102. Cures in Care Initiative lead network grant program. Sec. 103. Cures in Care Initiative Collaborative. Sec. 104. Definitions for Cures in Care Initiative and related activities. Sec. 105. Data standards with respect to data sharing. Sec. 106. Clinical trial oversight modernization. Sec. 107. Updates to patient costs and payment for participation in clinical trials. TITLE II--MODERNIZED PRECLINICAL AND EARLY-STAGE CLINICAL DEVELOPMENT Sec. 201. Modernized evidence generation through new approach methodologies. Sec. 202. Modernized phase 1 clinical trial oversight. Sec. 203. Global regulatory alignment to modernize clinical development. Sec. 204. Minimum United States representation in clinical trials. Sec. 205. Food and Drug Administration Rare Disease Innovation Hub. TITLE III--ENHANCED FOOD AND DRUG ADMINISTRATION REGULATIONS TO SUPPORT INNOVATION Sec. 301. Resolving clinical holds and improving clinical trial efficiency. Sec. 302. Mutual recognition of GMP standards. Sec. 303. Pathway for competitive generic therapies. Sec. 304. Biosimilar biological products. Sec. 305. Certification of patent information in certain applications for biological products. Sec. 306. GAO report. Sec. 307. Definitions. TITLE IV--PRECISION ONCOLOGY MODERNIZATION Sec. 401. Findings and purpose. Sec. 402. Oncology Center of Excellence. Sec. 403. Labeling revisions for genomic exclusions in oncology drugs. TITLE V--AMERICAN FRONTIER BIOBANK Sec. 501. Establishment of the American Frontier Biobank. TITLE I--EMBEDDING CLINICAL STUDIES IN ROUTINE HEALTH CARE

SEC. 101. CURES IN CARE INITIATIVE.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment

Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions

Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines

Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration

Sec. 101(a), new §499B(h)–(i) · Economic Freedom — Requires FDA external engagement and guidance within 18 months on decentralized trials, central IRBs, electronic consent, monitoring and real-world evidence. Mechanism: guidance and existing FDA authority

Sec. 101(a), new §499B(j)(1)–(2) · Economic Freedom — Requires annual public/congressional progress reports and evaluations after three and five years. Mechanism: agency reporting

Sec. 101(a), new §499B(l); Sec. 101(b)(1)–(2) · Economic Freedom — Authorizes $500 million annually FY2027–2031 for the initiative, and revises FDA Innovation Account transfers to $20m/$60m/$70m/$75m/$70m in FY2027–2031 and related appropriation authorization. Distinguish authorized appropriations from mandated transfers. Affected: federal programs and award recipients

Sec. 101(a), new §499B(c)(6)(B)–(C), (i)(1)–(3) · Privacy and Due Process — Requires coordination on electronic consent, interoperable clinical/real-world data, confidentiality protections, monitoring and central IRB reliance. Mechanism: program standards and FDA guidance

Sec. 101(a), new §499B(a)–(b) · Government Power — Establishes an FDA Center for Clinical Trial Innovation and a Cures in Care Initiative, with HHS, FDA and NIH coordination. Mechanism: statutory administrative duties

Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers

(a) In General.--Part J of title IV of the Public Health Service Act (42 U.S.C. 290c et seq.) is amended by adding at the end the following: ``SEC. 499B. CURES IN CARE INITIATIVE ESTABLISHMENT.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 101(a), new §499B(a)–(b) · Government Power — Establishes an FDA Center for Clinical Trial Innovation and a Cures in Care Initiative, with HHS, FDA and NIH coordination. Mechanism: statutory administrative duties

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(a) Center for Clinical Trial Innovation.--The Secretary shall establish the Center for Clinical Trial Innovation (in this section referred to as the `Center') within the Center for Drug Evaluation and Research of the Food and Drug Administration to carry out the Initiative established under subsection (b), to be headed by a director.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 101(a), new §499B(a)–(b) · Government Power — Establishes an FDA Center for Clinical Trial Innovation and a Cures in Care Initiative, with HHS, FDA and NIH coordination. Mechanism: statutory administrative duties

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(b) Establishment of Cures in Care Initiative.--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 101(a), new §499B(a)–(b) · Government Power — Establishes an FDA Center for Clinical Trial Innovation and a Cures in Care Initiative, with HHS, FDA and NIH coordination. Mechanism: statutory administrative duties

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(1) In general.--The Secretary, acting through the Assistant Secretary of Health shall continue a Cures in Care Initiative (in this section referred to as the `Initiative') to expand, enhance, and promote routine point-of-care clinical trials, including through the establishment and support of broad-based clinical trial networks (in this section referred to as a `lead network'), for the purpose of accelerating the development of new treatments and cures by generating clinical evidence faster and through novel methods.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 101(a), new §499B(a)–(b) · Government Power — Establishes an FDA Center for Clinical Trial Innovation and a Cures in Care Initiative, with HHS, FDA and NIH coordination. Mechanism: statutory administrative duties

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(2) Coordination and implementation.--The Assistant Secretary of Health shall coordinate the activities of the Commissioner of Food and Drugs and the Director of the National Institutes of Health in implementing the Initiative.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 101(a), new §499B(a)–(b) · Government Power — Establishes an FDA Center for Clinical Trial Innovation and a Cures in Care Initiative, with HHS, FDA and NIH coordination. Mechanism: statutory administrative duties

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(3) Principal office.--The Secretary shall establish the Center for Clinical Trial Innovation (in this section referred to as the `Center') within the Center for Drug Evaluation and Research of the Food and Drug Administration to serve as the principal implementing office supporting the Assistant Secretary of Health in carrying out the Initiative established under subsection (a), to be headed by a director.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment

Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 101(a), new §499B(c)(6)(B)–(C), (i)(1)–(3) · Privacy and Due Process — Requires coordination on electronic consent, interoperable clinical/real-world data, confidentiality protections, monitoring and central IRB reliance. Mechanism: program standards and FDA guidance

Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(c) Duties.--In carrying out the Initiative, the Director shall--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(1) identify priority disease or mechanism areas for the purpose of implementing lead networks;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(2) establish lead networks for each such a priority disease or mechanism area by building on existing clinical trial networks and infrastructures;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment

Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(3) ensure each such network prioritizes the participation of less-resourced clinical trial settings;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment

Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(4) ensure each such network focuses on not less than-- ``(A) 1 high-burden chronic disease; and ``(B) 1 group of rare diseases that are related or similar to each other;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment

Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(5) designate a central institutional review board to review any routine point-of-care clinical trial carried out by a lead network pursuant to this subsection;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions

Sec. 101(a), new §499B(c)(6)(B)–(C), (i)(1)–(3) · Privacy and Due Process — Requires coordination on electronic consent, interoperable clinical/real-world data, confidentiality protections, monitoring and central IRB reliance. Mechanism: program standards and FDA guidance

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(6) coordinate actions carried out under the Initiative for purposes of addressing barriers to the conduct of routine point-of-care clinical trials carried out by a lead network pursuant to this subsection, with respect to-- ``(A) shared or central institutional review board oversight; ``(B) patient consent, including electronic consent; ``(C) alignment of health information technology interoperability standards adopted by the Office of the National Coordinator for Health Information Technology, program data requirements administered by the Centers for Medicare & Medicaid Services and the real-world data standards maintained by the Commissioner of Food and Drugs, consistent with applicable privacy and confidentiality protections; ``(D) development of innovative clinical trial methods; ``(E) publication transparency and reproducibility; ``(F) digital tools and artificial intelligence to reduce the cost and burden of such clinical trials; ``(G) necessary infrastructure to implement a decentralized clinical trial network, in a hub-and- spoke model; and ``(H) governance of such clinical trials at multiple sites;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(7) establish an Food and Drug Administration-endorsed clinical trial site certification program; and

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(8) in consultation with the Director of the National Center for Advancing Translational Sciences award grants and enter into contracts, cooperative agreements, and other transactions, including as authorized under sections 499A(g) and 499C.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(d) Rapid Implementation.--The Director shall--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(1) establish not less than 3 lead networks under subsection (c) not later than 1 year after the date of enactment of this subsection; and

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(2) upon establishment of such lead networks, develop the plan described in subsection (e).

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment

Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(e) Implementation Plan for Expanding Activities.--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment

Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(1) In general.--Not later than 3 years after the date of enactment of this subsection, the Director shall implement a comprehensive implementation plan describing how the Initiative will broadly extend covered activities to the public and private development of medical products, including stretch goals with timeframes for-- ``(A) achieving expanded patient access and site access to routine point-of-care clinical trials, including ensuring patient access at 60 percent of health care delivery sites and for 90 percent of eligible patients that participate in a clinical trial carried out by a lead network established under subsection (c); ``(B) reducing the cost of such a clinical trial, including approaching a 30 to 50 percent reduction in cost per patient and a 30 percent reduction in accrual time; ``(C) enhancing any impact of such a clinical trial, including ensuring that 90 percent of patients participating in such a clinical trial obtain a timely, independently reviewed, and publicly reported result; and ``(D) assessing if lead networks are improving trial execution, including site activation timelines, time to first patient enrolled, enrollment and retention performance, data quality, monitoring burden, technology and workflow readiness, and the long-term research readiness of participating sites.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(2) Publication.--Not later than 3 years after the date of enactment of this paragraph, the Director shall make available to the public on the website of the Department of Health and Human Services the implementation plan implemented under paragraph (1).

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(3) Covered activity defined.--For purposes of paragraph (1), the term `covered activity' means-- ``(A) identifying priority disease or mechanism areas under subsection (c) for the purpose of implementing broad-based point-of-care clinical trial networks; or ``(B) establishing a lead network under such subsection for each such priority disease or mechanism area.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration

Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers

``(f) Collaboration and Consultation.--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration

``(1) Required collaboration and consultation.--In carrying out the Initiative, the Director shall collaborate and consult with-- ``(A) the Administrator of the Centers for Medicare & Medicaid Services; ``(B) the Director of the Advanced Research Projects Agency-Health; ``(C) the Administrator of the Health Resources and Services Administration; ``(D) the Office of the National Coordinator for Health Information Technology; ``(E) the Director of the Center for Biologics Evaluation and Research; ``(F) the Office of the Assistant Secretary of Health; and ``(G) representatives from-- ``(i) health care organizations in a lead network; ``(ii) network users, including researchers and clinical trial administrators; ``(iii) provider groups that do not directly collaborate with lead networks, including health systems, academic medical centers, and specialty medical societies; ``(iv) private and nonprofit organizations funding such organizations and groups; ``(v) patient advocacy organizations; ``(vi) contract research organizations; ``(vii) technology partners; and ``(viii) such other partner organizations as the Director determines appropriate.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration

``(2) Additional collaboration and consultation.--In addition to the collaboration and consultation required under paragraph (1), the Director may, as appropriate, collaborate and consult with-- ``(A) the Secretary of Veterans Affairs; and ``(B) the Secretary of Defense, including the Director of the Defense Health Agency.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment

Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration

Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers

``(g) Training and Technical Assistance.--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment

Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration

``(1) In general.--In carrying out the Initiative, the Director, in consultation with the Director of the National Center for Advancing Translational Sciences, shall provide training and technical assistance to-- ``(A) a lead network established under subsection (c); ``(B) a health care organization or other partner organization seeking to participate in a routine point- of-care clinical trial carried out by a lead network; ``(C) any entity that applies for a grant, cooperative agreement, contract, or other transaction under section 499C but does not receive such grant, cooperative agreement, contract, or other transaction; and ``(D) an emerging biotechnology company.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment

Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration

``(2) Contents.--In providing training and technical assistance under paragraph (1), the Director may address clinical development and regulatory subjects, including-- ``(A) protocol development; ``(B) regulatory interactions with the Food and Drug Administration; ``(C) data infrastructure integration; ``(D) sponsor and site engagement in designing, conducting, and evaluating clinical trials; ``(E) sustainability planning; and ``(F) general public education on clinical trials and their potential risks and benefits.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment

Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration

``(3) Format.--The Director shall make these training and technical assistance materials available in an online resource center, including resources on-- ``(A) staff training materials; ``(B) trial-network participation; ``(C) technology support; ``(D) data quality assessments; ``(E) Institutional Review Board templates and best practices; ``(F) study startup; and ``(G) capacity building.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment

Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration

``(4) Priority.--In carrying out this subsection, the Director shall give priority to less-resourced clinical trial settings.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration

``(5) Contracts and cooperative agreements for training.-- The Director may enter into contracts or cooperative agreements with entities, such as the Reagan-Udall Foundation for the Food and Drug Administration established under section 770 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379dd), to-- ``(A) establish training programs; and ``(B) hold meetings for health care organizations, clinical research organizations, technology partners, and patient-led organizations participating in a lead network established under subsection (c).

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(h)–(i) · Economic Freedom — Requires FDA external engagement and guidance within 18 months on decentralized trials, central IRBs, electronic consent, monitoring and real-world evidence. Mechanism: guidance and existing FDA authority

Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers

``(h) External Engagement.--The Commissioner of Food and Drugs shall establish and expand the external engagement capacity of the Center through the performance commitments under section 736B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379h-2).

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(h)–(i) · Economic Freedom — Requires FDA external engagement and guidance within 18 months on decentralized trials, central IRBs, electronic consent, monitoring and real-world evidence. Mechanism: guidance and existing FDA authority

Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers

``(i) FDA Guidance.--Not later than 18 months after the date of enactment of this subsection, the Commissioner of Food and Drugs shall, in consultation with the Director, issue any draft or final guidance as may be necessary to carry out this section, including with respect to--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(h)–(i) · Economic Freedom — Requires FDA external engagement and guidance within 18 months on decentralized trials, central IRBs, electronic consent, monitoring and real-world evidence. Mechanism: guidance and existing FDA authority

``(1) guidelines for carrying out routine point-of-care clinical trial networks, including governance, data monitoring, and application of an innovative clinical trial method, drawing on existing Food and Drug Administration guidance for platform studies;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(h)–(i) · Economic Freedom — Requires FDA external engagement and guidance within 18 months on decentralized trials, central IRBs, electronic consent, monitoring and real-world evidence. Mechanism: guidance and existing FDA authority

``(2) any update to guidance on decentralized clinical trials, remote monitoring of such trials, and real-world data and real-world evidence; and

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(h)–(i) · Economic Freedom — Requires FDA external engagement and guidance within 18 months on decentralized trials, central IRBs, electronic consent, monitoring and real-world evidence. Mechanism: guidance and existing FDA authority

``(3) reliance on central institutional review boards and electronic consent in routine point-of-care clinical trials.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(j)(1)–(2) · Economic Freedom — Requires annual public/congressional progress reports and evaluations after three and five years. Mechanism: agency reporting

Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers

``(j) Reports.--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(j)(1)–(2) · Economic Freedom — Requires annual public/congressional progress reports and evaluations after three and five years. Mechanism: agency reporting

``(1) Annual reports.--Not later than 1 year after the date of enactment of this paragraph, and annually thereafter, the Director shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate, and make available to the public on the website of the Department, a report on, with respect to the period covered by the report, the progress of the Initiative in advancing routine point-of- care clinical trials, with respect to each priority disease or mechanism area and lead network established under subsection (c), including-- ``(A) progress addressing any barrier described in such subsection; ``(B) the availability and performance of any routine point-of-care clinical trial in the United States; ``(C) any trend in the United States with respect to such clinical trials; and ``(D) the participation rate of less-resourced clinical trial settings in each such lead network.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(j)(1)–(2) · Economic Freedom — Requires annual public/congressional progress reports and evaluations after three and five years. Mechanism: agency reporting

``(2) Evaluation reports.-- ``(A) 3-year report.--Not later than 3 years after the date of enactment of this subparagraph, the Director shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report containing-- ``(i) an evaluation of-- ``(I) the outcome of any coordination, collaboration, and consultation required under this section, including the performance of each lead network established under subsection (c); ``(II) any expanded patient access and site access to routine point-of- care clinical trials that is attributable to the Initiative; ``(III) any improvement in the participation rate of less-resourced clinical trial settings that is attributable to the Initiative; ``(IV) any improvement in the participation rate of emerging biotechnology sponsors within the lead network; and ``(V) alignment of interagency action under this section; and ``(ii) any recommendation for additional legislative action to accelerate progress in carrying out routine point-of-care clinical trials and developing medical products. ``(B) 5-year report.--Not later than 5 years after the date of enactment of this subparagraph, the Director shall submit a report in such manner and containing such information as required under subparagraph (A).

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers

Sec. 304(a)(4)–(6), amended PHSA §351(k)(4), amended PHSA §351(k)(6) · Property Rights — Revises biosimilar interchangeability and preserves qualifying unexpired first-interchangeable exclusivity during transition; affects biologic applicants and exclusivity holders. Mechanism: FDA biologics licensure

``(k) Medical Product Defined.--In this section, the term `medical product' means--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

``(1) a drug or device, as defined in section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321); or

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

``(2) a biological product, as defined in section 351 of this Act.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 101(a), new §499B(l); Sec. 101(b)(1)–(2) · Economic Freedom — Authorizes $500 million annually FY2027–2031 for the initiative, and revises FDA Innovation Account transfers to $20m/$60m/$70m/$75m/$70m in FY2027–2031 and related appropriation authorization. Distinguish authorized appropriations from mandated transfers. Affected: federal programs and award recipients

Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers

``(l) Authorization of Appropriations.--In addition to any funds made available in the FDA Innovation Account under section 1002(b)(2)(A) of the 21st Century Cures Act (Public Law 114-255) and any amount made available under section 499C, there is authorized to be appropriated to carry out this section $500,000,000 for each of fiscal years 2027 through 2031, to remain available until expended.''.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

(b) FDA Innovation Account.--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

(1) Transfer of direct spending savings.--Section 1002(b)(2)(A) of the 21st Century Cures Act (Public Law 114- 255) is amended to read as follows: ``(A) In general.--The following amounts shall be transferred to the Account from the general fund of the Treasury: ``(i) For fiscal year 2027, $20,000,000. ``(ii) For fiscal year 2028, $60,000,000. ``(iii) For fiscal year 2029, $70,000,000. ``(iv) For fiscal year 2030, $75,000,000. ``(v) For fiscal year 2031, $70,000,000.''.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

(2) Authorization of appropriations.--Section 1002(b)(3) of the 21st Century Cures Act (Public Law 114-255) is amended by striking ``2017 through 2025'' each place such term appears and inserting ``2027 through 2031''.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

(3) FDA activities.--Section 1002(b)(4) of the 21st Century Cures Act (Public Law 114-255) is amended to read as follows:

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 101(a), new §499B(a)–(b) · Government Power — Establishes an FDA Center for Clinical Trial Innovation and a Cures in Care Initiative, with HHS, FDA and NIH coordination. Mechanism: statutory administrative duties

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(4) FDA activities.--The activities authorized to be funded under this section are the activities under-- ``(A) section 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357); ``(B) section 1014 of such Act (21 U.S.C. 399g); and ``(C) section 499B of the Public Health Service Act, as added by section 101(a) of the Faster Clinical Trials Act.''.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

(c) Conforming Amendment.--Part J of Title IV of the Public Health Service (42 U.S.C. 290c et seq.) is further amended by striking ``advanced research projects agency-health'' in the part heading and inserting ``advanced health research projects''.

SEC. 102. CURES IN CARE INITIATIVE LEAD NETWORK GRANT PROGRAM.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Part J of title IV of the Public Health Service Act (42 U.S.C. 290c et seq.) is amended by adding at the end the following: ``SEC. 499C. CURES IN CARE INITIATIVE LEAD NETWORK GRANT PROGRAM.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(a) In General.--Not later than 5 years after the date of enactment of this subsection, the Commissioner of Food and Drugs, in consultation with the Director of the Center for Clinical Trial Innovation, and the Director of the National Institutes of Health, acting through the Center for Advancing Translational Sciences and the Advanced Research Projects Agency-Health, (in this section referred to as the `Commissioner and Director') shall make grants to, or enter into cooperative agreements, contracts, or other transactions with, not fewer than 3 lead networks established under section 499B(c) to--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(1) achieve not later than 3 years after the date on which an appropriation is first made under subsection (e), measurable improvements in the clinical evidence base for each priority disease or mechanism area for which such network was established; and

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(2) enable broader implementation of routine point-of- care clinical trials beyond such lead network.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(b) Use of Funds.--The Commissioner and Director may require a lead network that receives a grant, or enters into a cooperative agreement, contract, or other transaction, under this section to use any funding received through such grant, cooperative agreement, contract, or transaction to--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(1) implement the data sharing standards described under section 105 of the Faster Clinical Trials Act;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(2) implement site data infrastructure and clinical research technology;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(3) leverage existing clinical trial networks, Federal digital health and artificial intelligence initiatives, and virtual participation options, consistent with good clinical practice;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(4) provide a plan for reliable collection and sharing of data on covariates, treatments, outcomes, and adverse events with respect to the applicable disease or mechanism area;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(5) support, as appropriate-- ``(A) phase 2 and 3 clinical trials; ``(B) label expansion studies; ``(C) comparative effectiveness studies; and ``(D) post-market commitments and phase 4 commitments;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(6) include sites and patients from less-resourced clinical trial settings;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(7) include patients from populations not primarily served by academic health centers;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(8) include emerging biotechnology companies;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(9) establish grants specifically for less-resourced sites, including federally qualified health centers, to enable participation;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(10) collaborate or partner with multiple commercial developers of medical products (as defined in section 499B) that are active in the applicable disease or mechanism area; and

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(11) include a plan for sustainability with respect to a routine point-of-care clinical trial carried out by such platform, including a description of-- ``(A) any partial startup funding from a non- Federal source; ``(B) an additional study on the common trial platform to be carried out after the date on which the period described in subsection (c) ends; and ``(C) an understanding of how lead networks will maintain infrastructure and research beyond initial Federal support, including long-term site readiness, staffing and workforce support, technology maintenance, continued community-site participation, sponsor adoption and utilization, and the operational resources necessary to support multiple studies over time.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(c) Duration.--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(1) In general.--Subject to paragraph (2), a grant, cooperation agreement, contract, or other transaction under this section shall be for a period of not more than 5 years.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(2) Extension for material contribution.--The Commissioner and Director may extend the 5-year period described in paragraph (1) by not more than 3 years if the Commissioner and Director determine that such extension will materially contribute to fulfillment of the implementation plan required under section 499B.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(d) Evaluation.--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(1) In general.--The Cures in Care Initiative Collaborative established under section 499D shall evaluate any activity carried out using any funds received through a grant, cooperative agreement, contract, or transaction under this section, including-- ``(A) a partnership between a lead network and a sponsor or health care organization that are additional sites of care; ``(B) compared to traditional baselines, the cost of-- ``(i) recruiting, enrolling, and treating each patient enrolled in a routine point-of- care clinical trial; and ``(ii) completing each such trial; ``(C) any research impact such an activity has on-- ``(i) such clinical trials; ``(ii) any site in which such a clinical trial is performed; and ``(iii) any effect on the evidence base; ``(D) inclusion of less-resourced clinical trial settings; and ``(E) any opportunity to increase scaling and sustainability with respect to such a clinical trial carried out by a lead network that receives such funds, including-- ``(i) a maintenance plan for clinical trial sites to continue participating after the initial grant period ends; and ``(ii) continued education for sites and training opportunities for staff.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(2) Publication.--Not later than 3 years after the date of enactment of this paragraph, and annually thereafter, the Collaborative shall make available to the public on the website of the Department of Health and Human Services the evaluation carried out under paragraph (1).

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(e) Budget Clarification; Agency Contributions.--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(1) Authorization of appropriations.--There is authorized to be appropriated to carry out this section such sums as necessary for each of fiscal years 2027 through 2031, to remain available until expended.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(2) Common fund.--The Commissioner and Director may reserve to carry out this section any amounts made available under paragraph (1) for the Common Fund established under section 402A(c)(1).

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(3) Budget clarification.--Any budget request of the President shall specify an amount for carrying out this section.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions

Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors

Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting

Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation

Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law

Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication

``(4) Agency contributions.--In addition to any funds made available under section 402A(a)(3), the Secretary may transfer funds from other departmental agencies and programs to carry out the Initiative established under section 499B, including the grant program established under this section, provided such funds do not supplant funding under such section and such transfer will further the authorized programs of the contributing agency or program.''.

SEC. 103. CURES IN CARE INITIATIVE COLLABORATIVE.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

Part J of title IV of the Public Health Service Act (42 U.S.C. 290c et seq.) is amended by adding at the end the following: ``SEC. 499D. CURES IN CARE INITIATIVE COLLABORATIVE.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(a) In General.--The Secretary, acting through the Director of NIH and the Director of the Center for Clinical Trial Innovation, shall establish, through entering into a contract, cooperative agreement, memorandum of understanding, or other mechanism, a public-private partnership, to be known as the Cures in Care Initiative Collaborative (in this section referred to as the `Collaborative'), to--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(1) promote routine point-of-care clinical trials, including the development of novel trial methodologies;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(2) promote the elimination of barriers to trial initiation and completion; and

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(3) support lead networks under the Cures in Care Initiative established under section 499B.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(b) Required Activities.--The Collaborative shall--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(1) establish user groups, workshops, and other forums for sponsors, contract research organizations, health care organizations, technology providers, patient organizations, and Federal agencies to identify and address implementation barriers to routine point-of-care clinical trials;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(2) provide technical assistance, including on protocol development, regulatory interactions, and data infrastructure, to sponsors of routine point-of-care clinical trials and lead networks that receive a grant, or enter into a cooperative agreement, contract, or other transaction, under section 499C;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(3) support sandbox testing of innovations in trial design, data infrastructure, consent, and governance prior to broader adoption of such innovations;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(4) evaluate incentives to support and sustain site participation in clinical trial networks;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(5) maintain public reporting on progress, barriers, and outcomes of routine point-of-care clinical trial innovation;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(6) coordinate with-- ``(A) existing public-private partnerships on routine point-of-care clinical trial innovation; ``(B) existing research infrastructures within the National Institutes of Health and the Advanced Research Projects Agency-Health; and ``(C) the Center for Medicare and Medicaid Innovation established under section 1115A of the Social Security Act (42 U.S.C. 1315a), except that the Collaborative may not direct, or be directed by, such Center;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(7) carry out the evaluation required under section 499C(d);

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(8) support practical technology and operational enablement of lead networks, including development and testing of integrated technology packages that can provide participating sites with interoperable tools, standardized workflows, training, implementation support, monitoring and data quality capabilities, and centralized technical assistance for less resourced sites; and

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(9) assess opportunities to centralize services, including patient recruitment, to reduce the burden of participation for clinical trial sites.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight

Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process

Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA

``(c) Federal Advisory Committee Act Applicability.--Chapter 10 of title 5, United States Code, shall not apply to the Collaborative.''.

SEC. 104. DEFINITIONS FOR CURES IN CARE INITIATIVE AND RELATED ACTIVITIES.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation

Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope

Part J of title IV of the Public Health Service Act (42 U.S.C. 290c et seq.) is amended by adding at the end the following: ``SEC. 499E. DEFINITIONS FOR CURES IN CARE INITIATIVE AND RELATED ACTIVITIES. ``In this part:

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation

Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope

``(1) Clinical investigation.--The term `clinical investigation' has the meaning given such term in section 50.3 of title 21, Code of Federal Regulations (or any successor regulation).

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation

Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope

``(2) Innovative clinical trial method.--The term `innovative clinical trial method' includes adaptive, decentralized, Bayesian, platform, and external-control trial designs, as such terms are described in guidance issued by the Food and Drug Administration, including pursuant to section 3021 of the 21st Century Cures Act (21 U.S.C. 355 note) and section 3606 of the Consolidated Appropriations Act, 2023 (21 U.S.C. 360a-1 note).

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation

Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope

``(3) Lead disease or mechanism area.--The term `lead disease or mechanism area' means a disease, condition, or disease-mechanism area that presents substantial opportunity for scaled, reusable platforms for routine point-of-care clinical trials.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation

Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope

``(4) Lead network.--The term `lead network' means a network of participating health care organizations for a lead disease or mechanism area.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation

Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope

``(5) Less-resourced clinical trial setting.--The term `less-resourced clinical trial setting' means a health care organization or provider that--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation

Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope

``(A) is located in, or primarily serves, a medically underserved community (as defined in section 799B(6) of this Act); or

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation

Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope

``(B) is-- ``(i) a Federally qualified health center (as defined in section 1861 of the Social Security Act (42 U.S.C. 1395x)); ``(ii) a rural health clinic (as defined in such section); ``(iii) a critical access hospital (as defined in such section); ``(iv) a health center that, during the period in which such center is in a lead network established under section 499B(c) of this Act, receives a grant under section 330; ``(v) a hospital that, during such period, receives a disproportionate share payment under section 1886(d)(5)(F) of the Social Security Act (42 U.S.C. 1395ww(d)(5)(F)); ``(vi) a facility owned or operated by the Indian Health Service; ``(vii) a facility operated by an Indian Tribe, Tribal organization, or an urban Indian organization (as such terms are defined in section 4 of the Indian Health Care Improvement Act (25 U.S.C. 1603)); or ``(viii) a health care provider that, during such period, receives a grant under title XXVI of the Public Health Service Act (42 U.S.C. 300ff et seq.) (commonly known as the Ryan White HIV/AIDS program).

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation

Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope

``(6) Routine point-of-care clinical trial.--The term `routine point-of-care clinical trial' means a clinical investigation of a medical product (as defined in section 499B of this Act) that--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation

Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope

``(A) is integrated into clinical practice, including routine in-person or virtual visits;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation

Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope

``(B) includes health providers as investigators;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation

Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope

``(C) may be conducted in a primary care setting, an outpatient care setting, the home of a patient participating in such investigation, or a similar location; and

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation

Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope

``(D) may follow a streamlined protocol and procedures focused on essential data collection generating or incorporating real-world data from an electronic or other health record.''.

SEC. 105. DATA STANDARDS WITH RESPECT TO DATA SHARING.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards

Sec. 105(a)–(f); Sec. 106(a)–(c); Sec. 107(a)–(c) · Government Power — Assigns interagency data standards, FDA IRB rulemaking/monitoring, and CMS trial coverage and participant-payment rules

(a) In General.--Not later than 18 months after the date of enactment of this Act, the Administrator of the Centers for Medicare & Medicaid Services, the Commissioner of Food and Drugs, and the National Coordinator for Health Information Technology (in this section referred to as the ``Administrator'') shall establish a list of data standards for the purpose of facilitating the exchange of patient data for routine point-of-care clinical trials and contribution to Federal datasets using established common data models.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards

Sec. 105(a)–(f); Sec. 106(a)–(c); Sec. 107(a)–(c) · Government Power — Assigns interagency data standards, FDA IRB rulemaking/monitoring, and CMS trial coverage and participant-payment rules

(b) Required Contents.--In establishing the list under subsection (a), the Administrator shall include--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards

(1) the United States Core Data for Interoperability;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards

(2) the Fast Healthcare Interoperability Resources standard maintained by Health Level Seven;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards

(3) the Clinical Data Acquisition Standards Harmonization maintained by the Clinical Data Interchange Standards Consortium; and

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards

(4) the Study Data Tabulation Model maintained by such Consortium.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards

Sec. 105(a)–(f); Sec. 106(a)–(c); Sec. 107(a)–(c) · Government Power — Assigns interagency data standards, FDA IRB rulemaking/monitoring, and CMS trial coverage and participant-payment rules

(c) Updates to List.--Not less than once every 3 years, the Administrator shall update the list of data standards established under subsection (a) to reflect new or successor standards adopted by the National Coordinator for Health Information Technology pursuant to section 3001 of the Public Health Service Act (42 U.S.C. 300jj-11).

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards

Sec. 105(a)–(f); Sec. 106(a)–(c); Sec. 107(a)–(c) · Government Power — Assigns interagency data standards, FDA IRB rulemaking/monitoring, and CMS trial coverage and participant-payment rules

(d) Technical Specifications and Validation Pathways for Data Exchange.--Not later than 12 months after the date of enactment of this Act, the Administrator shall make available to the public on the website of the Department technical specifications and validation pathways by which data exchanged, in a manner consistent with the data standards included on the list established under subsection (a), may be translated for regulatory submission.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(e) · Privacy and Due Process — Permits CMS linkage/tokenization capabilities for trial data only in compliance with HIPAA, the Privacy Act and 42 CFR part 2. Affected: patient data holders and participants. Mechanism: incorporated privacy statutes

Sec. 105(a)–(f); Sec. 106(a)–(c); Sec. 107(a)–(c) · Government Power — Assigns interagency data standards, FDA IRB rulemaking/monitoring, and CMS trial coverage and participant-payment rules

(e) Privacy-Preserving Data Sharing.--The Administrator may implement data linkage and tokenization capabilities maintained by the Centers for Medicare & Medicaid Services to support data sharing in routine point-of-care clinical trials in compliance with--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(e) · Privacy and Due Process — Permits CMS linkage/tokenization capabilities for trial data only in compliance with HIPAA, the Privacy Act and 42 CFR part 2. Affected: patient data holders and participants. Mechanism: incorporated privacy statutes

(1) the Health Insurance Portability and Accountability Act of 1996 (Public Law 104-191);

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(e) · Privacy and Due Process — Permits CMS linkage/tokenization capabilities for trial data only in compliance with HIPAA, the Privacy Act and 42 CFR part 2. Affected: patient data holders and participants. Mechanism: incorporated privacy statutes

(2) section 552a of title 5, United States Code (commonly referred to as the ``Privacy Act of 1974''); and

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(e) · Privacy and Due Process — Permits CMS linkage/tokenization capabilities for trial data only in compliance with HIPAA, the Privacy Act and 42 CFR part 2. Affected: patient data holders and participants. Mechanism: incorporated privacy statutes

(3) part 2 of title 42, Code of Federal Regulations (or any successor regulation), relating to confidentiality of substance use disorder patient records.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(f) · Privacy and Due Process — Directs federal assessment of real-world data and AI/digital tools for product-efficacy, label-expansion and regulatory decisionmaking. Mechanism: agency assessment; no new individual disclosure penalty

Sec. 105(a)–(f); Sec. 106(a)–(c); Sec. 107(a)–(c) · Government Power — Assigns interagency data standards, FDA IRB rulemaking/monitoring, and CMS trial coverage and participant-payment rules

(f) Implementation Plan.--Not later than 90 days after the date of enactment of this Act, the Administrator shall make available to the public on the website of the Department an implementation plan that--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(f) · Privacy and Due Process — Directs federal assessment of real-world data and AI/digital tools for product-efficacy, label-expansion and regulatory decisionmaking. Mechanism: agency assessment; no new individual disclosure penalty

(1) includes milestones for carrying out each activity under subsections (a) through (e);

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(f) · Privacy and Due Process — Directs federal assessment of real-world data and AI/digital tools for product-efficacy, label-expansion and regulatory decisionmaking. Mechanism: agency assessment; no new individual disclosure penalty

(2) designates lead officials at the Centers for Medicare & Medicaid Services, the Food and Drug Administration, and the Office of the National Coordinator for Health Information Technology to carry out such activities;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(f) · Privacy and Due Process — Directs federal assessment of real-world data and AI/digital tools for product-efficacy, label-expansion and regulatory decisionmaking. Mechanism: agency assessment; no new individual disclosure penalty

(3) describes how such activities align with the Cures in Care Initiative established under section 499B of the Public Health Service Act, as added by section 101 of this Act; and

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 105(f) · Privacy and Due Process — Directs federal assessment of real-world data and AI/digital tools for product-efficacy, label-expansion and regulatory decisionmaking. Mechanism: agency assessment; no new individual disclosure penalty

(4) describes how technology will be implemented in daily clinical workflows, such as telehealth, remote monitoring, eCOA/ePRO, wearables and connected devices, eConsent, EDC, eSource, and EHR integration, with appropriate expectations for validation, interoperability, data quality, privacy, cybersecurity and regulatory use.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

(g) Amendment to FDA Guidance.--Not later than 12 months after the list of data standards is established under paragraph (1), the Commissioner of Food and Drugs shall update the guidance entitled ``Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products'' (89 Fed. Reg. 60430; issued July 25, 2024) (or successor guidance) to clarify how a person may use data shared in compliance with such standards when submitting an application seeking approval of a medical product, including for--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

(1) demonstrating the effectiveness of-- (A) medical products approved under section 506 or 515B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356; 21 U.S.C. 360e-3); (B) a previously approved medical product for a new indication of use; and (C) a drug designated as an orphan drug under section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb);

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

(2) assessing fit-for-purpose validation of digital health technologies and artificial intelligence tools that capture or analyze such data for clinical investigations of medical products; and

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

(3) assessing how real-world evidence contained in Federal datasets could be leveraged to support regulatory decision- making for medical product approval applications.

SEC. 106. CLINICAL TRIAL OVERSIGHT MODERNIZATION.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 106(a)(1)–(4) · Economic Freedom — Requires one IRB for covered multi-institutional clinical investigations, allowing alternatives when the sponsor demonstrates necessity; FDA must make implementing rules within one year. Affected: sponsors and IRBs. Mechanism: existing human-subjects/FDA compliance

Sec. 106(a)(1)–(3) · Privacy and Due Process — Centralizes IRB review with limited alternatives; changes review procedure rather than eliminating human-subject protections. Mechanism: FDA rulemaking and IRB oversight

(a) Single IRB Requirement for Certain Clinical Investigations.--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 106(a)(1)–(4) · Economic Freedom — Requires one IRB for covered multi-institutional clinical investigations, allowing alternatives when the sponsor demonstrates necessity; FDA must make implementing rules within one year. Affected: sponsors and IRBs. Mechanism: existing human-subjects/FDA compliance

Sec. 106(a)(1)–(3) · Privacy and Due Process — Centralizes IRB review with limited alternatives; changes review procedure rather than eliminating human-subject protections. Mechanism: FDA rulemaking and IRB oversight

(1) In general.--Subject to paragraph (2), a sponsor of multi-institutional or cooperative clinical investigations of medical products regulated under parts 45 and 56 of title 21, Code of Federal Regulations (or any successor regulations), shall designate a single institutional review board with respect to the review of such investigation.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 106(a)(1)–(4) · Economic Freedom — Requires one IRB for covered multi-institutional clinical investigations, allowing alternatives when the sponsor demonstrates necessity; FDA must make implementing rules within one year. Affected: sponsors and IRBs. Mechanism: existing human-subjects/FDA compliance

Sec. 106(a)(1)–(3) · Privacy and Due Process — Centralizes IRB review with limited alternatives; changes review procedure rather than eliminating human-subject protections. Mechanism: FDA rulemaking and IRB oversight

(2) Exception.--If, in an investigational new drug application or investigational device exemption application, the sponsor described in paragraph (1) demonstrates that an alternative manner of review is necessary and the designation of only one institutional review board is not appropriate, such sponsor may, with respect to a clinical investigation-- (A) rely on the review of an institutional review board local to a site for such clinical investigation; (B) enter into a joint review arrangement with institutional review boards; or (C) make such other arrangement to avoid a duplication of effort.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 106(a)(1)–(4) · Economic Freedom — Requires one IRB for covered multi-institutional clinical investigations, allowing alternatives when the sponsor demonstrates necessity; FDA must make implementing rules within one year. Affected: sponsors and IRBs. Mechanism: existing human-subjects/FDA compliance

Sec. 106(a)(1)–(3) · Privacy and Due Process — Centralizes IRB review with limited alternatives; changes review procedure rather than eliminating human-subject protections. Mechanism: FDA rulemaking and IRB oversight

(3) Rulemaking.--Not later than 12 months after the date of enactment of this Act, the Commissioner of Food and Drugs shall issue such rules as may be necessary to implement this subsection, including-- (A) amending parts 50 and 56 of title 21, Code of Federal Regulations (or any successor regulation); and (B) ensuring implementation of section 3023 of the 21st Century Cures Act (Public Law 114-255).

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 106(a)(1)–(4) · Economic Freedom — Requires one IRB for covered multi-institutional clinical investigations, allowing alternatives when the sponsor demonstrates necessity; FDA must make implementing rules within one year. Affected: sponsors and IRBs. Mechanism: existing human-subjects/FDA compliance

(4) Definitions.--In this subsection: (A) Investigational device exemption application.-- The term ``investigational device exemption application'' means an application submitted pursuant to part 812 of title 21, Code of Federal Regulations (or any successor regulation), to request an exemption for an investigational device (as defined in section 812.3 of such part). (B) Multi-institutional clinical investigation.-- The term ``multi-institutional clinical investigation'' means a clinical investigation conducted at not less than two institutions under a single protocol.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 106(b)(2) · Property Rights — Requires IRB-disclosure rules to preserve confidential commercial information and trade secrets while publishing decision summaries. Affected: sponsors and research institutions. Mechanism: HHS/FDA/NIH rulemaking and existing confidentiality protections

Sec. 106(b)(1)–(3) · Privacy and Due Process — Requires rules within one year to publish IRB deliberation summaries and decision bases, while protecting health information, trade secrets and confidential business information, preferably through ClinicalTrials.gov. Mechanism: agency rulemaking

(b) IRB Transparency in Decision-Making.--Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Assistant Secretary of Health, Commissioner of Food and Drugs, and the Director of the National Institutes of Health shall issue such rules as may be necessary to amend title 21 and title 45, Code of Federal Regulations (and any successor regulations), to--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 106(b)(1)–(3) · Privacy and Due Process — Requires rules within one year to publish IRB deliberation summaries and decision bases, while protecting health information, trade secrets and confidential business information, preferably through ClinicalTrials.gov. Mechanism: agency rulemaking

(1) expand the public disclosure of Institutional Review Board (referred to as ``IRB'' in this section) deliberations, including summaries of key issues in submitted protocols and summary bases of decisions;

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 106(b)(2) · Property Rights — Requires IRB-disclosure rules to preserve confidential commercial information and trade secrets while publishing decision summaries. Affected: sponsors and research institutions. Mechanism: HHS/FDA/NIH rulemaking and existing confidentiality protections

Sec. 106(b)(1)–(3) · Privacy and Due Process — Requires rules within one year to publish IRB deliberation summaries and decision bases, while protecting health information, trade secrets and confidential business information, preferably through ClinicalTrials.gov. Mechanism: agency rulemaking

(2) maintain the confidentiality of protected health information, commercial confidential data, and trade secrets in such disclosures of IRB deliberations; and

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 106(b)(1)–(3) · Privacy and Due Process — Requires rules within one year to publish IRB deliberation summaries and decision bases, while protecting health information, trade secrets and confidential business information, preferably through ClinicalTrials.gov. Mechanism: agency rulemaking

(3) implement such disclosures, to the extent practicable, through the ClinicalTrials.gov website (or a successor website) maintained by the National Library of Medicine.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 106(c) · Economic Freedom — Expands FDA bioresearch monitoring through user-fee performance commitments. Mechanism: existing FDA inspection/oversight

(c) Bioresearch Monitoring Capacity.--The Commissioner of Food and Drugs shall expand and enhance the bioresearch monitoring capacity of the Food and Drug Administration through the performance commitments under section 736B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379h-2).

SEC. 107. UPDATES TO PATIENT COSTS AND PAYMENT FOR PARTICIPATION IN CLINICAL TRIALS.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 107(a)(1)(A)–(B), (a)(2) · Individual Rights — Requires CMS within 18 months to clarify Medicare routine-cost coverage for qualifying point-of-care trials, including digital/remote care, align quality data standards, and address use of such evidence in national coverage decisions. Affected: Medicare beneficiaries, providers, sponsors. Mechanism: existing Medicare coverage determinations; no standalone fine

(a) Enabling Coverage of Patient Costs and Use of Evidence.--

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 107(a)(1)(A)–(B), (a)(2) · Individual Rights — Requires CMS within 18 months to clarify Medicare routine-cost coverage for qualifying point-of-care trials, including digital/remote care, align quality data standards, and address use of such evidence in national coverage decisions. Affected: Medicare beneficiaries, providers, sponsors. Mechanism: existing Medicare coverage determinations; no standalone fine

(1) Routine care cost coverage clarification.-- (A) In general.--Not later than 18 months after the date of enactment of this Act, the Administrator of the Centers for Medicare & Medicaid Services shall issue guidance, or update the National Coverage Determination for Routine Costs in Clinical Trials, to clarify that a routine point-of-care clinical trial is a qualifying clinical trial, such that coverage is available under the Medicare program under title XVIII of the Social Security Act (42 U.S.C. 1395 et seq.) for routine costs incurred in connection with such trial, including items and services furnished in connection with such trial through digital health tools and through providers operating in digital-first or remote care modalities. (B) Alignments with data standards.--The Administrator shall align the Centers for Medicare & Medicaid Services quality measurement initiatives with the data standards established under section 105.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 107(a)(1)(A)–(B), (a)(2) · Individual Rights — Requires CMS within 18 months to clarify Medicare routine-cost coverage for qualifying point-of-care trials, including digital/remote care, align quality data standards, and address use of such evidence in national coverage decisions. Affected: Medicare beneficiaries, providers, sponsors. Mechanism: existing Medicare coverage determinations; no standalone fine

(2) Point-of-care evidence for coverage guidance.--Not later than 18 months after the date of enactment of this Act, the Administrator shall issue or update guidance on how evidence from a routine point-of-care clinical trial may be applied to-- (A) national coverage determinations (as defined in section 1869(f)(1)(B) of the Social Security Act (42 U.S.C. 1395ff(f)(1)(B))) and updates thereto; and (B) coverage of items and services subject to conditions of evidence development established by the Secretary under section 1862(a)(1)(A) of the Social Security Act (42 U.S.C. 1395y(a)(1)(A)), commonly referred to as coverage with evidence development.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 107(b)–(c) · Individual Rights — Requires HHS within one year to make rules for fair compensation of clinical-trial participants and participating sites, taking account of research risks, burdens and undue influence. Affected: participants, investigators and sponsors. Mechanism: future rules and existing research oversight

(b) Clinical Trial Participant Payment.--Not later than 1 year after the date of enactment of this Act, the Secretary, in consultation with the Commissioner of Food and Drugs and the Director of the Office of Human Research Protections shall issue such rules as may be necessary with respect to compensation for participants in a clinical trial as to ensure compensation is commensurate with the risks and burdens associated with the research and are not construed as constituting potential undue influence.

Sec. 101–107 — 201–205, 301–307, 401–403, and 501

Sec. 107(b)–(c) · Individual Rights — Requires HHS within one year to make rules for fair compensation of clinical-trial participants and participating sites, taking account of research risks, burdens and undue influence. Affected: participants, investigators and sponsors. Mechanism: future rules and existing research oversight

(c) Clinical Trial Site Participant Payment.--Not later than 1 year after the date of enactment of this Act, the Secretary, in consultation with the Commissioner of Food and Drugs and the Director of the National Institutes of Health, shall issue such rules as may be necessary with respect to fair compensation for site participants in a clinical trial. TITLE II--MODERNIZED PRECLINICAL AND EARLY-STAGE CLINICAL DEVELOPMENT

SEC. 201. MODERNIZED EVIDENCE GENERATION THROUGH NEW APPROACH METHODOLOGIES.

Sec. 201(a)(1)–(2) · Economic Freedom — Requires FDA guidance/evidence frameworks within two years on in-vitro, in-silico and other new methodologies for preclinical studies and IND submissions. Mechanism: future guidance and existing drug approval

Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties

(a) Guidance for Implementation of New Approach Methodologies.--

Sec. 201(a)(1)–(2) · Economic Freedom — Requires FDA guidance/evidence frameworks within two years on in-vitro, in-silico and other new methodologies for preclinical studies and IND submissions. Mechanism: future guidance and existing drug approval

Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties

(1) In general.--Not later than 2 years after the date of enactment of this Act, the Secretary, acting through the Commissioner of Food and Drugs (in this section referred to as the ``Commissioner''), shall issue guidance and evidence frameworks, including through amending existing guidance or frameworks, to facilitate the implementation of new approach methodologies for the purpose of streamlining and accelerating-- (A) preclinical pharmacology and toxicology studies; (B) submission of investigational new drug applications; and (C) early clinical phases of drug development.

Sec. 201(a)(1)–(2) · Economic Freedom — Requires FDA guidance/evidence frameworks within two years on in-vitro, in-silico and other new methodologies for preclinical studies and IND submissions. Mechanism: future guidance and existing drug approval

Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties

(2) Contents.--In issuing guidance under paragraph (1), the Commissioner shall-- (A) identify leading and novel use cases for in vitro and in silico technology, including by-- (i) expanding on streamlined nonclinical programs and acceptable new approach methodologies; (ii) describing additional opportunities to apply such technology to toxicology; (iii) describing how to validate complex in vitro and in silico technology as new approach methodologies; and (iv) describing the use of human-derived in vitro and ex vivo systems where a nonclinical species does not express, or does not adequately recapitulate binding to, the human target of a targeted biological product, including where a species-specific surrogate molecule would otherwise be required; (B) implement pathways for the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research to validate new approach methodologies, for patients with a rare disease or other serious and life-threatening conditions, including the program established under section 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357) and the plausible mechanism framework for rare diseases implemented by the Food and Drug Administration; (C) incorporate-- (i) the information obtained through the workshops and meetings described in subsection (b); and (ii) the policies established under subsection (c); and (D) clarify the types and amount of data required to validate a new approach methodology for a context of use, and to expand such validated contexts of use.

Sec. 201(b)(2), (c)(1)(B)–(C) · Property Rights — Requires consideration of intellectual-property/proprietary protections as incentives for sponsors to share preclinical-methodology data. Affected: drug sponsors and technology developers. Mechanism: future FDA validation policy; no immediate compulsory patent transfer

Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender

Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties

(b) Public Engagement.--The Commissioner, in consultation with the Director of the National Institutes of Health, shall hold workshops and public meetings to engage with sponsors, physicians, researchers, patients, and other stakeholders to, with respect to the development and validation of new approach methodologies, including in vitro and in silico technology--

Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender

Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties

(1) encourage precompetitive collaboration between sponsors, researchers, technology developers, and preclinical research organizations;

Sec. 201(b)(2), (c)(1)(B)–(C) · Property Rights — Requires consideration of intellectual-property/proprietary protections as incentives for sponsors to share preclinical-methodology data. Affected: drug sponsors and technology developers. Mechanism: future FDA validation policy; no immediate compulsory patent transfer

Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender

Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties

(2) identify incentives for sponsor participation, including protection of intellectual property or such other proprietary protection, to encourage data sharing from completed preclinical projects; and

Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender

Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties

(3) advance collaborative analyses and validations of such methodologies to reduce development costs and increase the acceptance of such methodologies for preclinical testing and regulatory requirements, including by reducing or eliminating animal testing for new medical products.

Sec. 201(b)(2), (c)(1)(B)–(C) · Property Rights — Requires consideration of intellectual-property/proprietary protections as incentives for sponsors to share preclinical-methodology data. Affected: drug sponsors and technology developers. Mechanism: future FDA validation policy; no immediate compulsory patent transfer

Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender

Sec. 201(c)(1)(B) · Privacy and Due Process — Includes data-security and proprietary safeguards in the new-methodology validation policy. Mechanism: FDA guidance

Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties

(c) Regulatory Innovation.--The Commissioner, in consultation with the Director of the National Institutes of Health and the Director of the Advanced Research Projects Agency-Health shall, using the information obtained through the workshops and meetings described in subsection (b), establish a policy or platform for accelerated and precompetitive data sharing for, and analyses and validation of, new approach methodologies, that includes--

Sec. 201(b)(2), (c)(1)(B)–(C) · Property Rights — Requires consideration of intellectual-property/proprietary protections as incentives for sponsors to share preclinical-methodology data. Affected: drug sponsors and technology developers. Mechanism: future FDA validation policy; no immediate compulsory patent transfer

Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender

Sec. 201(c)(1)(B) · Privacy and Due Process — Includes data-security and proprietary safeguards in the new-methodology validation policy. Mechanism: FDA guidance

Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties

(1) an incentive for sponsor participation, including a method for regulatory validation of-- (A) digital and artificial intelligence tools; (B) appropriate data security standards; and (C) proprietary protection;

Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender

Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties

(2) a novel or improved validation method for a new approach methodology based on-- (A) data for such methodology; and (B) traditional preclinical validation data for the clinical investigation of a medical product, regardless of whether such investigation proceeded to human studies;

Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender

Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties

(3) a sustainable method of funding, including-- (A) a sponsor applying to a Federal grant or contract program; (B) the Secretary establishing a Federal grant or contract program; or (C) the Secretary recommending that Congress-- (i) establish a new Federal grant or contract program for the purposes described in this section; or (ii) take other legislative action to establish such method of funding; and

Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender

Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties

(4) with respect to regulatory submissions, guidelines for enhanced collaboration with international regulatory authorities to advance the use and acceptance of a validated new approach methodology.

SEC. 202. MODERNIZED PHASE 1 CLINICAL TRIAL OVERSIGHT.

Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation

Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(a) In General.--The Secretary shall establish an expedited procedure for review and initiation of lower-risk phase 1 trials, including through--

Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation

Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(1) issuing guidance, including through amending existing guidance; and

Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation

Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(2) establishing the pilot program under subsection (b).

Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation

Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules

Sec. 202(b)(2)–(5) · Privacy and Due Process — Provides qualification and safety review for delegated third-party trial assessments; high-risk categories are not automatically eligible for expedited review. Mechanism: FDA/IRB controls

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(b) Pilot Program.--

Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation

Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(1) In general.--The Secretary shall establish a pilot program for the third-party review of lower-risk phase 1 trials.

Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation

Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules

Sec. 202(b)(2)–(5) · Privacy and Due Process — Provides qualification and safety review for delegated third-party trial assessments; high-risk categories are not automatically eligible for expedited review. Mechanism: FDA/IRB controls

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(2) Qualified third parties.-- (A) Consideration as qualified third party.--A third party is qualified to review a lower-risk phase 1 trial under the pilot program established under paragraph (1) if such third party-- (i) is-- (I) an institutional review board; or (II) such other third party, as determined by the Secretary; (ii) has technical competency to-- (I) review toxicology data; and (II) ensure Chemistry, Manufacturing, and Controls (in this section referred to as ``CMC'') data is compliant with good manufacturing practices in a manner that is commensurate with any review carried out by the Commissioner of Foods and Drugs with respect to investigational new drug applications; and (iii) complies with the criteria established under subparagraph (B). (B) Qualification criteria.--Using the criteria to accredit or deny accreditation to persons who request to perform the duties specified in section 523 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360m) as a model, the Secretary shall establish criteria by which a third party may be considered a qualified third party under subparagraph (A)(iii).

Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation

Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules

Sec. 202(b)(2)–(5) · Privacy and Due Process — Provides qualification and safety review for delegated third-party trial assessments; high-risk categories are not automatically eligible for expedited review. Mechanism: FDA/IRB controls

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(3) Establishment of pilot program criteria.--In carrying out the pilot program established under paragraph (1), the Secretary shall establish criteria for a qualified third party to review a lower-risk phase 1 trial, including the use of lead use cases and compliance with best practices for the effective, efficient, and timely ethical review and safety oversight of such trial.

Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation

Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules

Sec. 202(b)(2)–(5) · Privacy and Due Process — Provides qualification and safety review for delegated third-party trial assessments; high-risk categories are not automatically eligible for expedited review. Mechanism: FDA/IRB controls

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(4) Enhanced oversight.--In carrying out the pilot program established under paragraph (1), the Secretary shall-- (A) collect performance data with respect to such pilot program; (B) assess any review carried out under such pilot program to ensure that the quality of such review is commensurate with any review carried out by the Commissioner of Foods and Drugs with respect to investigational new drug applications; and (C) audit any qualified third party who conducts such a review to ensure program integrity.

Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation

Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules

Sec. 202(b)(2)–(5) · Privacy and Due Process — Provides qualification and safety review for delegated third-party trial assessments; high-risk categories are not automatically eligible for expedited review. Mechanism: FDA/IRB controls

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(5) Extension to higher-risk phase 1 trials.--The Secretary shall assess-- (A) any information obtained under paragraph (4); and (B) the desirability of expanding such pilot program to include the review of higher-risk phase 1 trials by-- (i) establishing and piloting pre- certification standards with additional or enhanced requirements, as appropriate based on the risk of such trial, including for study conduct and monitoring, manufacturing, and adverse event mitigation; (ii) developing specific guidance and pilot support for-- (I) a qualified institutional review board to review such a trial for a cell or gene therapy, or a gene editing product; (II) clear and specific regulatory discussions for filing investigational new drug applications; (III) CMC-readiness by a sponsor or investigator of such a trial; and (IV) a dose escalation approach for such a trial; and (iii) holding workshops, and publishing findings from such workshops, to support a potentially generalizable pre-certification process for early-stage studies of a cell or gene therapy, or a gene editing product.

Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(6) Regulatory harmonization.--The Secretary shall assess whether subpart A of part 46 of title 45, Code of Federal Regulations (or any successor regulation), should be amended to ensure regulatory consistency with any information obtained under paragraphs (4) and (5).

Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(c) Requirements With Respect to Establishing Expedited Procedure.--For purposes of carrying out this section, the Secretary shall--

Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(1) establish criteria for classifying a phase 1 trial as a lower-risk phase 1 trial or a higher-risk phase 1 trial;

Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(2) assess relevant global regulatory programs with decentralized and expedited review and approval of phase 1 trials, including the Clinical Trial Notification scheme established by the Parliament of Australia in the Therapeutic Goods Act 1989, and any amendments thereto; and

Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(3) incorporate any findings from such assessment into the expedited procedure established under subsection (a).

Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(d) Appropriate Manufacturing Standards.--

Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(1) Proposed rule.--Not later than 1 year after the date of enactment of this Act, the Secretary shall issue a proposed rule to revise such sections in title 21, Code of Federal Regulations (or any successor regulations), relating to current good manufacturing practices for drugs, as may be necessary to ensure that, for an unapproved new drug or investigational drug intended for use in a lower-risk phase 1 trial, the burden of complying with CMC does not unnecessarily impede the initiation of such trial.

Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(2) Considerations.--In determining whether to revise a regulation under paragraph (1), the Secretary shall consider-- (A) the criteria established under subsection (c)(1); (B) the risk associated with lower-risk phase 1 trials; (C) the limited number of patients typically enrolled in phase 1 trials; (D) the use of small-batch, non-continuous manufacturing processes; (E) the clinical setting of lower-risk phase 1 trials, including-- (i) academic medical centers; or (ii) in the case of routine point-of-care clinical trials, primary care and outpatient care settings; and (F) the extent to which guidance for investigational drugs intended for use in lower-risk phase 1 trials can be included in regulation to provide greater regulatory certainty.

Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(3) Final rule.--Not later than 1 year after the date on which the comment period ends for the proposed rule issued under paragraph (1), the Secretary shall-- (A) incorporate any information obtained under subsection (b)(4); and (B) finalize such rule.

Sec. 202(e)(1)–(3) · Economic Freedom — Defines higher-risk trials by genome modification, replication, irreversible biological effects, immune risk, prior clinical holds or unreasonable significant harm; lower-risk includes minimal-harm, exploratory/subtherapeutic or investigator-initiated trials. Mechanism: eligibility classification, not a new penalty

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(e) Definitions.--In this section:

Sec. 202(e)(1)–(3) · Economic Freedom — Defines higher-risk trials by genome modification, replication, irreversible biological effects, immune risk, prior clinical holds or unreasonable significant harm; lower-risk includes minimal-harm, exploratory/subtherapeutic or investigator-initiated trials. Mechanism: eligibility classification, not a new penalty

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(1) Higher-risk phase 1 trial.--The term ``higher-risk phase 1 trial'' means a phase 1 trial-- (A) of an investigational drug that is intended to result in, or is capable of resulting in, modification of the genome of a human cell, including by integration, insertion, deletion, or base or prime editing; (B) of an investigational drug that is replication- competent or capable of horizontal transfer; (C) of an investigational drug the biological activity of which cannot be discontinued by cessation of dosing; (D) of an investigational drug intended to produce sustained engagement of immune effector cells with an antigen expressed on essential non-malignant human tissue; (E) of an investigational drug for which any prior clinical investigation has been placed on clinical hold pursuant to section 312.42 of title 21, Code of Federal Regulations (or any successor regulation); or (F) that is more likely to expose human subjects to an unreasonable and significant risk of illness or injury.

Sec. 202(e)(1)–(3) · Economic Freedom — Defines higher-risk trials by genome modification, replication, irreversible biological effects, immune risk, prior clinical holds or unreasonable significant harm; lower-risk includes minimal-harm, exploratory/subtherapeutic or investigator-initiated trials. Mechanism: eligibility classification, not a new penalty

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(2) Lower-risk phase 1 trial.--The term ``lower-risk phase 1 trial'' means a phase 1 trial-- (A) that presents a minimal potential for harm to a patient; (B) that is an exploratory or phase 0 study of subtherapeutic or non-toxic doses with no therapeutic intent; or (C) that is a study initiated by an investigator.

Sec. 202(e)(1)–(3) · Economic Freedom — Defines higher-risk trials by genome modification, replication, irreversible biological effects, immune risk, prior clinical holds or unreasonable significant harm; lower-risk includes minimal-harm, exploratory/subtherapeutic or investigator-initiated trials. Mechanism: eligibility classification, not a new penalty

Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines

(3) Phase 1 trial.--The term ``phase 1 trial'' means phase 1 of a clinical investigation of a previously untested drug, as described in section 312.21 of title 21, Code of Federal Regulations (or any successor regulation).

SEC. 203. GLOBAL REGULATORY ALIGNMENT TO MODERNIZE CLINICAL DEVELOPMENT.

Sec. 203(a), amended FDCA §803(b)(2), (d)(1)–(2) · Economic Freedom — Adds international Good Clinical Practice recognition and FDA global coordination for foreign trials and real-world data. Mechanism: FDA inspection/approval

Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers

(a) In General.--Section 803 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 383) is amended--

Sec. 203(a), amended FDCA §803(b)(2), (d)(1)–(2) · Economic Freedom — Adds international Good Clinical Practice recognition and FDA global coordination for foreign trials and real-world data. Mechanism: FDA inspection/approval

Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers

(1) in subsection (b)-- (A) in paragraph (1), by striking ``, and'' and inserting a semicolon; (B) by redesignating paragraph (2) as paragraph (4); and (C) by adding after paragraph (1) the following:
``(2) the standard, entitled `Good Clinical Practice', maintained by the International Council for Harmonisation;''; and

Sec. 203(a), amended FDCA §803(b)(2), (d)(1)–(2) · Economic Freedom — Adds international Good Clinical Practice recognition and FDA global coordination for foreign trials and real-world data. Mechanism: FDA inspection/approval

Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers

(2) by adding at the end the following: ``(d)(1) The Secretary shall expand and coordinate efforts, including through enhanced international collaboration, to ensure compliance with the standard, entitled `Good Clinical Practice', maintained by the International Council for Harmonisation for clinical trials conducted outside the United States.
``(2) The Secretary shall, in consultation with relevant nations and the International Council for Harmonisation, foster global regulatory alignment to modernize clinical early-stage medical product development, integrate real-world data and digital health information into clinical investigations, and ensure regulatory acceptance of investigations conducted by clinical trial networks embedded in routine practice.''.

Sec. 203(a), amended FDCA §803(b)(2), (d)(1)–(2) · Economic Freedom — Adds international Good Clinical Practice recognition and FDA global coordination for foreign trials and real-world data. Mechanism: FDA inspection/approval

Sec. 203(b), new FDCA §704(i)(1)–(2) · Economic Freedom — Requires inspected clinical establishments to pre-certify GCP compliance; requires verification for covered biotechnology companies of concern and authorizes inspection-cost fees. Affected: site owners/operators/agents. Mechanism: FDA inspection, fees and approval decisions

Sec. 203(b), new FDCA §704(i)(1)–(2) · Privacy and Due Process — Imposes pre-certification and federal verification/inspection of specified clinical sites, with inspection cost fees. Mechanism: FDA inspection authority

Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers

Sec. 302(b), amended FDCA §803(b)(3) · Economic Freedom — Requires bioresearch monitoring to seek reciprocal inspection reliance, reduced duplicate U.S. inspections and risk-based oversight. Mechanism: FDA regulatory collaboration

Sec. 203(b) · Government Power — most other agency study, guidance and grant provisions create no new standalone criminal penalty. Appropriation authorizations are not assumed to have been funded. The five titles contain no general sunset; the FY2027–2031 limits on some authorities do not sunset the permanent Biobank authorization

(b) Enhancing Data Integrity and Oversight of Clinical Trials at Sites of Concern.--Section 704 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 374) is amended by adding at the end the following: ``(i)(1) With respect to an owner, operator, or agent in charge of an establishment carrying out a clinical investigation intended to support an application under section 505 of this Act or section 351 of the Public Health Service Act (42 U.S.C. 262), the Secretary shall, as part of the inspection of such establishment under this section--
``(A) require such owner, operator, or agent to pre-certify that such clinical investigation complies with the standard, entitled `Good Clinical Practice', maintained by the International Council for Harmonisation; and
``(B) verify, on-site or remotely, that, prior to the acceptance of data from any clinical trial site, contract research organization, or data management vendor that meets the criteria of a biotechnology company of concern (as defined in section 851(f)(2) of the National Defense Authorization Act for Fiscal Year 2026 (Public Law 119-60)), such clinical investigation complies with-- ``(i) such standard; and ``(ii) data security protocols.
``(2) The Secretary may require an owner, operator, or agent described in paragraph (1) to pay a fee to cover any cost related to the activities described in such paragraph.''.

Sec. 203(c)(1)–(2) · Economic Freedom — Permits FDA to demand source data, audit trails, translated consent records and sample chains of custody for foreign phase 1–2 studies, and reject data for noncompliance. Affected: sponsors/investigators. Mechanism: FDA refusal to accept clinical data

Sec. 203(c)(1)(A)–(D), (c)(2) · Privacy and Due Process — Authorizes compelled foreign patient-level source data, audit trails, translated informed-consent records, specimen custody and other documentation; FDA may reject evidence if the sponsor refuses. Affected: foreign trial participants and sponsors. Mechanism: evidence exclusion at FDA

Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers

Sec. 203(c)(2) · Government Power — and may charge inspection fees

Sec. 203(c)(1)–(2) · Government Power — alongside long-term longitudinal genomic/clinical data integration

(c) Strengthening Foreign Early-Phase Data Verification.--

Sec. 203(c)(1)–(2) · Economic Freedom — Permits FDA to demand source data, audit trails, translated consent records and sample chains of custody for foreign phase 1–2 studies, and reject data for noncompliance. Affected: sponsors/investigators. Mechanism: FDA refusal to accept clinical data

Sec. 203(c)(1)(A)–(D), (c)(2) · Privacy and Due Process — Authorizes compelled foreign patient-level source data, audit trails, translated informed-consent records, specimen custody and other documentation; FDA may reject evidence if the sponsor refuses. Affected: foreign trial participants and sponsors. Mechanism: evidence exclusion at FDA

Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers

Sec. 203(c)(1)–(2) · Government Power — alongside long-term longitudinal genomic/clinical data integration

(1) Documentation requirement.--The Secretary may, with respect to any patient-level data from a phase 1 or phase 2 clinical investigation conducted outside of the United States, require a sponsor or investigator to submit documentation of such patient-level data for purposes of ensuring the integrity of such investigation, such as-- (A) source data and audit trails for each primary or secondary endpoint tested in such investigation; (B) records of informed consent, translated into English; (C) the chain of custody for each biological sample and test article used in such investigation; and (D) other documentation as deemed necessary by the Secretary.

Sec. 203(c)(1)–(2) · Economic Freedom — Permits FDA to demand source data, audit trails, translated consent records and sample chains of custody for foreign phase 1–2 studies, and reject data for noncompliance. Affected: sponsors/investigators. Mechanism: FDA refusal to accept clinical data

Sec. 203(c)(1)(A)–(D), (c)(2) · Privacy and Due Process — Authorizes compelled foreign patient-level source data, audit trails, translated informed-consent records, specimen custody and other documentation; FDA may reject evidence if the sponsor refuses. Affected: foreign trial participants and sponsors. Mechanism: evidence exclusion at FDA

Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers

Sec. 203(c)(2) · Government Power — and may charge inspection fees

Sec. 203(c)(1)–(2) · Government Power — alongside long-term longitudinal genomic/clinical data integration

(2) Refusal of data.--The Secretary may refuse to accept such patient-level data if a sponsor or investigator does not comply with the requirement to provide documentation pursuant to paragraph (1).

Sec. 203(a), amended FDCA §803(b)(2), (d)(1)–(2) · Economic Freedom — Adds international Good Clinical Practice recognition and FDA global coordination for foreign trials and real-world data. Mechanism: FDA inspection/approval

Sec. 203(d) · Economic Freedom — Requires FDA within 18 months to clarify consequences for delaying/denying inspections. Mechanism: guidance and existing inspection law

Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers

(d) Guidance on Data Integrity and Inspection Access.--Not later than 18 months after the date of enactment of this Act, the Secretary shall revise the guidance issued by the Food and Drug Administration, entitled ``Guidance for Industry: Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection'', (issued June 2024) to provide clarification on any action the Secretary will take if a person does not comply with any requirement established by the Secretary under section 704(i) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (b) of this section.

SEC. 204. MINIMUM UNITED STATES REPRESENTATION IN CLINICAL TRIALS.

Sec. 204(a)–(b) · Economic Freedom — Requires U.S.-enrolled patients in specified pivotal studies and restricts approvals relying only on foreign clinical data, subject to statutory exceptions/waivers where domestic studies are unavailable, impracticable, or emergency conditions justify. Affected: drug and biologic sponsors. Mechanism: FDA marketing-application review

Sec. 204(a)–(b) · Government Power — Adds FDA authority to enforce domestic-patient participation and grant defined waivers

(a) In General.--The Secretary of Health and Human Services shall require that each pivotal study submitted in support of an application under section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) or section 351(a) of the Public Health Service Act (42 U.S.C. 262(a)) meet the requirements of subsection (b).

Sec. 204(a)–(b) · Economic Freedom — Requires U.S.-enrolled patients in specified pivotal studies and restricts approvals relying only on foreign clinical data, subject to statutory exceptions/waivers where domestic studies are unavailable, impracticable, or emergency conditions justify. Affected: drug and biologic sponsors. Mechanism: FDA marketing-application review

Sec. 204(b) · Privacy and Due Process — Gives FDA waiver/exception discretion for U.S. enrollment and foreign-data requirements, including public-health emergencies. Mechanism: FDA application decisions

Sec. 204(a)–(b) · Government Power — Adds FDA authority to enforce domestic-patient participation and grant defined waivers

(b) U.S. Participation.--A pivotal study contained in an application under section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) or section 351(a) of the Public Health Service Act (42 U.S.C. 262(a))--

Sec. 204(a)–(b) · Economic Freedom — Requires U.S.-enrolled patients in specified pivotal studies and restricts approvals relying only on foreign clinical data, subject to statutory exceptions/waivers where domestic studies are unavailable, impracticable, or emergency conditions justify. Affected: drug and biologic sponsors. Mechanism: FDA marketing-application review

Sec. 204(b) · Privacy and Due Process — Gives FDA waiver/exception discretion for U.S. enrollment and foreign-data requirements, including public-health emergencies. Mechanism: FDA application decisions

Sec. 204(a)–(b) · Government Power — Adds FDA authority to enforce domestic-patient participation and grant defined waivers

(1) may not be based solely on foreign clinical data;

Sec. 204(a)–(b) · Economic Freedom — Requires U.S.-enrolled patients in specified pivotal studies and restricts approvals relying only on foreign clinical data, subject to statutory exceptions/waivers where domestic studies are unavailable, impracticable, or emergency conditions justify. Affected: drug and biologic sponsors. Mechanism: FDA marketing-application review

Sec. 204(b) · Privacy and Due Process — Gives FDA waiver/exception discretion for U.S. enrollment and foreign-data requirements, including public-health emergencies. Mechanism: FDA application decisions

Sec. 204(a)–(b) · Government Power — Adds FDA authority to enforce domestic-patient participation and grant defined waivers

(2) shall include patients enrolled at clinical investigation sites in the United States, including as part of a multi-national clinical trial to support such application;

Sec. 204(a)–(b) · Economic Freedom — Requires U.S.-enrolled patients in specified pivotal studies and restricts approvals relying only on foreign clinical data, subject to statutory exceptions/waivers where domestic studies are unavailable, impracticable, or emergency conditions justify. Affected: drug and biologic sponsors. Mechanism: FDA marketing-application review

Sec. 204(b) · Privacy and Due Process — Gives FDA waiver/exception discretion for U.S. enrollment and foreign-data requirements, including public-health emergencies. Mechanism: FDA application decisions

Sec. 204(a)–(b) · Government Power — Adds FDA authority to enforce domestic-patient participation and grant defined waivers

(3) shall align with international harmonization efforts, including the guidance issued by the International Council for Harmonisation, entitled ``General Principles for Planning and Design of Multi-Regional Clinical Trials'' (E17; adopted November 16, 2017); and

Sec. 204(a)–(b) · Economic Freedom — Requires U.S.-enrolled patients in specified pivotal studies and restricts approvals relying only on foreign clinical data, subject to statutory exceptions/waivers where domestic studies are unavailable, impracticable, or emergency conditions justify. Affected: drug and biologic sponsors. Mechanism: FDA marketing-application review

Sec. 204(b) · Privacy and Due Process — Gives FDA waiver/exception discretion for U.S. enrollment and foreign-data requirements, including public-health emergencies. Mechanism: FDA application decisions

Sec. 204(a)–(b) · Government Power — Adds FDA authority to enforce domestic-patient participation and grant defined waivers

(4) shall include any other evaluation metrics as determined by the Secretary, including if-- (A) the drug or biological product that is the subject of the application described in this Act is intended to treat a rare disease or condition; (B) the Secretary determines that foreign clinical data-- (i) is derived from a clinical investigation conducted in accordance with good clinical practice; (ii) is applicable to the United States population and United States medical practice; and (iii) is validated through an on-site inspection of the relevant trial site or other appropriate means, as determined by the Secretary; (C) clinical investigation sites in the United States are unavailable; (D) establishing a clinical investigation site in the United States is otherwise impracticable; or (E) a waiver is necessary to protect public health during a public health emergency.

SEC. 205. FOOD AND DRUG ADMINISTRATION RARE DISEASE INNOVATION HUB.

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

The Federal Food, Drug, and Cosmetic Act is amended by adding after section 1014 (21 U.S.C. 360ff-1) the following: ``SEC. 1014A. FOOD AND DRUG ADMINISTRATION RARE DISEASE INNOVATION HUB.

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(a) Food and Drug Administration Rare Disease Innovation Hub.-- The Secretary shall establish the Food and Drug Administration Rare Disease Innovation Hub (in this section referred to as the `Hub') as an Intercenter Institute described in section 1014 to--

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(1) advance regulatory science for a rare disease or condition;

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(2) provide technical assistance to review teams assessing rare disease medical products to ensure reviewer consistency and documentation of agreements upon acceptable trial designs;

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(3) promote innovation of rare disease medical products;

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(4) leverage lead networks (established in title I of the Faster Clinical Trials Act), interoperable technology and data infrastructure, and public-private collaboration mechanisms to advance natural history studies, distributed and platform clinical trials, biomarker and clinical outcome assessment development, and fit-for-purpose evidence generated from real- world data generation for rare diseases;

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(5) enhance coordination, alignment, and collaboration between the heads of the Directors listed in subsection (b)(1) and other Intercenter Institutes established under section 1014 with respect to the development and regulation of rare disease medical products;

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(6) foster and support dialogue and public-private partnerships with patients who have, and providers that treat, a rare disease or condition to ensure such development is patient-focused;

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(7) allow sponsors to consult with the Hub regarding questions, concerns, or deliberations throughout the review process; and

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(8) function as a point of escalation for sponsors of rare disease medical products to request re-review or consultation regarding review decisions.

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(b) Activities.--In addition to the activities of an Intercenter Institute described in section 1014, the Hub shall--

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(1) facilitate collaboration, information sharing, regulatory consistency, and cross-disciplinary training and product reviews with-- ``(A) the Office of Orphan Products Development; ``(B) the Center for Drug Evaluation and Research; ``(C) the Center for Biologics Evaluation and Research; ``(D) the Center for Devices and Radiological Health; and ``(E) the Oncology Center of Excellence; and

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(2) award grants, cooperative agreements, or contracts, or enter into memoranda of understanding, to-- ``(A) support natural history studies, the use of novel clinical trial designs, and the application of the plausible mechanism evidentiary framework; ``(B) accelerate the development and validation of early and novel biomarkers and endpoints for rare diseases or conditions, pursuant to section 507 of this Act and section 3208 of the Food and Drug Omnibus Reform Act (Public Law 117-328); ``(C) ensure targeted technical assistance is provided for-- ``(i) investigator-initiated clinical trials for medical products intended to treat rare diseases or conditions; and ``(ii) patient-sponsored development programs for such medical products; ``(D) hold meetings and workshops to engage directly with-- ``(i) rare disease patient organizations and families of patients with rare diseases or conditions; ``(ii) developers of rare disease medical products; and ``(iii) researchers and specialty medical societies; and ``(E) assist in addressing scientific, clinical, and policy issues related to the development and regulation of such products.

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(c) Public-Private Partnerships and Consortia.--The Hub shall foster public-private partnerships or consortia to support the activities required under this section, including initiatives to--

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(1) de-risk and facilitate access to manufacturing capacity, including at Federal laboratories and facilities, for-- ``(A) investigator-initiated clinical trials for rare disease medical products; and ``(B) patient-sponsored development programs for such medical products; and

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(2) support clinical trials for, and development of, such a medical product through a national network of clinical centers of excellence for rare diseases or conditions.

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(d) Report.--Not later than 9 months after the date of enactment of this subsection, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate, and make available to the public, a report containing recommendations on the development and regulation of a medical product intended to treat a rare disease or condition, including--

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(1) whether to selectively restore the establishment license application under section 351 of the Public Health Service Act (42 U.S.C. 262) to facilitate the manufacture of rare disease medical products by nontraditional sponsors; and

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(2) whether to enhance regulatory flexibility and manufacturing capacity for nontraditional sponsors, such as academic laboratories or patient organizations, of-- ``(A) an investigator-initiated clinical trial for a rare disease medical product; ``(B) a patient-sponsored development program for such a medical product; and ``(C) research and development for medical products intended to treat or diagnose very rare and n-of-1 diseases or conditions.

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(e) Funding.--

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(1) In general.--To carry out this section, the Secretary shall transfer to the Hub for each of fiscal years 2027 through 2031-- ``(A) $5,000,000 from the amounts made available in the FDA Innovation Account under section 1002(b)(2)(A) of the 21st Century Cures Act (Public Law 114-255); ``(B) $10,000,000 from the amounts made available under section 481A of the Public Health Service Act (42 U.S.C. 287a-2) for clinical research into, training in, and demonstration of diagnostic, prevention, control, and treatment methods for rare diseases; and ``(C) $15,000,000 from the amounts made available to carry out section 499A(f) of such Act (42 U.S.C. 290c(f)), related to cooperation of the Advanced Research Projects Agency-Health with the Food and Drug Administration to facilitate the development of medical products and projects that are the highest priorities to the Advanced Research Projects Agency-Health.

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(2) Budget clarification.--Any budget request of the President shall specify an amount for carrying out this section.

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(f) Definitions.--In this section:

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(1) Medical product.--The term `medical product' means-- ``(A) a drug or device, as defined in section 201 of this Act; or ``(B) a biological product, as defined in section 351 of the Public Health Service Act (42 U.S.C. 262).

Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process

Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards

Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations

Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions

``(2) Rare disease or condition.--The term `rare disease or condition' has the meaning given such term in section 526.''. TITLE III--ENHANCED FOOD AND DRUG ADMINISTRATION REGULATIONS TO SUPPORT INNOVATION

SEC. 301. RESOLVING CLINICAL HOLDS AND IMPROVING CLINICAL TRIAL EFFICIENCY.

Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight

Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval

Sec. 301(a)(6)–(7) · Privacy and Due Process — Requires clarification of confidential-information redaction and procedures for publishing FDA complete response letters and investigational/premarket application materials, including possible automation and pilot disclosure. Affected: applicants and public. Mechanism: FDA disclosure procedures subject to existing confidentiality law

Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031

(a) In General.--For purposes of improving the efficiency and integrity of clinical investigations, the Secretary shall address any root cause of a clinical hold imposed under section 312.42 of title 21, Code of Federal Regulations (or any successor regulation), or the disapproval or withdrawal of approval of an investigational device exemption under section 812.30 of such title (or any successor regulation), including--

Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight

Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval

Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031

(1) identifying common sources of noncompliance with such regulations and common causes of clinical holds and development delays, with a focus on first-time sponsors of a clinical trial and investigator-initiated clinical trials, IRBs, CROs and other experienced implementation and technology partners, research sites;

Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight

Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval

Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031

(2) developing and disseminating best practices for-- (A) compliance with good clinical practices; (B) efficient development, filing, and review of investigational new drug applications and investigational device exemptions; and (C) increasing the frequency and documentation of in-person meetings for sponsors of investigational new drug applications and investigational device exemptions in lieu of written responses to provide specific, authoritative, and consistent guidance with a focus on action items and enhancements;

Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight

Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval

Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031

(3) early and additional sponsor engagement consistent with, and additive to, the performance commitments under section 736B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379h-2) to-- (A) secure rapid alignment on a trial design in support of a complete application for a proposed indication of use; and (B) create additional opportunities for informal, rapid feedback to such a sponsor, including science- focused drug development meetings;

Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight

Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval

Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031

(4) increasing the use of external advisory committees;

Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight

Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval

Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031

(5) early and consistent integration of staff with requisite expertise in rare diseases or conditions, as appropriate, in review teams for the review of investigational and premarket new drug applications;

Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight

Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval

Sec. 301(a)(6)–(7) · Privacy and Due Process — Requires clarification of confidential-information redaction and procedures for publishing FDA complete response letters and investigational/premarket application materials, including possible automation and pilot disclosure. Affected: applicants and public. Mechanism: FDA disclosure procedures subject to existing confidentiality law

Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031

(6) clarifying what information qualifies to be redacted when disclosing complete response letters to the public;

Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight

Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval

Sec. 301(a)(6)–(7) · Privacy and Due Process — Requires clarification of confidential-information redaction and procedures for publishing FDA complete response letters and investigational/premarket application materials, including possible automation and pilot disclosure. Affected: applicants and public. Mechanism: FDA disclosure procedures subject to existing confidentiality law

Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031

(7) revising procedures and guidance for-- (A) clarifying what information must be redacted when publicly disclosing complete response letters and other investigational and premarket new drug application materials to the public; (B) developing and publicly disclosing novel redaction methods and tools, including automation or artificial intelligence; (C) the timely public disclosure of complete response letters and other investigational and premarket new drug application materials; and (D) the establishment of pilot programs to facilitate timely public access to such letters and such application materials; and

Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight

Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval

Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031

(8) creating a designated Food and Drug Administration contact for process and regulatory-navigation questions for emerging biotechnology companies.

Sec. 301(b) · Economic Freedom — Authorizes $500 million annually FY2027–2031 for process improvements, available until expended; not automatically appropriated

Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031

(b) Authorization of Appropriations.--There is authorized to be appropriated to carry out this section $500,000,000 for each of the fiscal years 2027 through 2031, to remain available until expended.

SEC. 302. MUTUAL RECOGNITION OF GMP STANDARDS.

Sec. 302(a), amended FDCA §809(a) · Economic Freedom — Broadens reliance on qualifying foreign government GMP inspections and related medical-product inspection recognition. Affected: manufacturers. Mechanism: FDA inspection law

Sec. 302(a)–(b) · Government Power — Expands foreign inspection recognition and international bioresearch monitoring coordination

(a) Recognition of Foreign Government Inspections.--Section 809 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 384e) is amended--

Sec. 302(a), amended FDCA §809(a) · Economic Freedom — Broadens reliance on qualifying foreign government GMP inspections and related medical-product inspection recognition. Affected: manufacturers. Mechanism: FDA inspection law

Sec. 302(a)–(b) · Government Power — Expands foreign inspection recognition and international bioresearch monitoring coordination

(1) in subsection (a)-- (A) in paragraph (2), by striking ``and'' at the end; (B) in paragraph (3), by striking the period at the end and inserting ``; and''; and (C) by inserting after paragraph (3) the following:

Sec. 302(a), amended FDCA §809(a) · Economic Freedom — Broadens reliance on qualifying foreign government GMP inspections and related medical-product inspection recognition. Affected: manufacturers. Mechanism: FDA inspection law

``(4) shall implement a procedure for exchanging inspection reports with a foreign government or an agency of a foreign government that the Secretary has entered into an arrangement or agreement with under this section to avoid duplicating an inspection in which a foreign establishment registered under section 510 was found to be in compliance with good manufacturing practice regulations promulgated under section 501.'';

Sec. 302(a), amended FDCA §809(a) · Economic Freedom — Broadens reliance on qualifying foreign government GMP inspections and related medical-product inspection recognition. Affected: manufacturers. Mechanism: FDA inspection law

Sec. 302(a)–(b) · Government Power — Expands foreign inspection recognition and international bioresearch monitoring coordination

(2) by redesignating subsection (c) as subsection (d);

Sec. 302(a), amended FDCA §809(a) · Economic Freedom — Broadens reliance on qualifying foreign government GMP inspections and related medical-product inspection recognition. Affected: manufacturers. Mechanism: FDA inspection law

Sec. 302(a)–(b) · Government Power — Expands foreign inspection recognition and international bioresearch monitoring coordination

(3) by inserting after subsection (b) the following:
``(c) Risk-Based Prioritization Plan.--For purposes of increasing the rate of inspections, the Secretary shall implement a plan for the use of risk-based prioritization for inspections of establishments registered under section 510, which shall include consideration of--
``(1) the history of such an establishment with respect to complying with good manufacturing practice regulations promulgated under section 520(f);
``(2) the inherent risk of the drug or device manufactured, prepared, propagated, compounded, or processed (as defined in section 510) at such establishment; and
``(3) the availability of recent inspection reports from a foreign government or an agency of a foreign government that the Secretary has entered into an arrangement or agreement with under this section.''; and
(4) in paragraph (2) of subsection (d), as redesignated by paragraph (2) of this section-- (A) by striking ``Beginning not later'' and inserting the following: ``(A) In general.--Beginning not later''; and (B) by adding at the end the following: ``(B) Reporting on mutual recognition.--The report under subparagraph (A) shall include, with respect to the period covered by the report an update on the status of any agreement the Secretary enters into with a foreign country under section 803 related to encouraging the mutual recognition of good manufacturing practice regulations promulgated under section 520(f) with respect to inspections.''.

Sec. 302(b), amended FDCA §803(b)(3) · Economic Freedom — Requires bioresearch monitoring to seek reciprocal inspection reliance, reduced duplicate U.S. inspections and risk-based oversight. Mechanism: FDA regulatory collaboration

Sec. 302(a)–(b) · Government Power — Expands foreign inspection recognition and international bioresearch monitoring coordination

(b) Expansion of Mutual Recognition Agreements to Bioresearch Monitoring.--Section 803(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 383(b)) is amended by inserting after paragraph (2), as inserted by section 203(a)(1)(C), the following:
``(3) the bioresearch monitoring program implemented by the Food and Drug Administration through compliance programs shall identify ways to-- ``(A) allow such countries to rely on any inspection conducted by the Food and Drug Administration related to an establishment performing clinical research; ``(B) reduce the regulatory burden on such an establishment in the United States; and ``(C) provide the Secretary with maximum flexibility to focus resources related to inspections and compliance on establishments that pose the greatest risk to data integrity or safety.''.

SEC. 303. PATHWAY FOR COMPETITIVE GENERIC THERAPIES.

Sec. 303(a)–(c) · Economic Freedom — Requires FDA to review the competitive-generic-therapy pathway within 12 months, report recommendations and begin implementing them within six months after submission, consulting stakeholders. Mechanism: FDA program implementation; no automatic product approval

Sec. 303(a)–(c) · Government Power — Requires FDA competitive-generic pathway study and implementation steps

(a) Review.--The Secretary shall review and provide recommendations to improve the pathway for competitive generic therapies established pursuant to section 506H of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356h) no later than 12 months after the date of the enactment of this Act.

Sec. 303(a)–(c) · Economic Freedom — Requires FDA to review the competitive-generic-therapy pathway within 12 months, report recommendations and begin implementing them within six months after submission, consulting stakeholders. Mechanism: FDA program implementation; no automatic product approval

Sec. 303(a)–(c) · Government Power — Requires FDA competitive-generic pathway study and implementation steps

(b) Improvement.--Following the review under paragraph (1), the Secretary shall--

Sec. 303(a)–(c) · Economic Freedom — Requires FDA to review the competitive-generic-therapy pathway within 12 months, report recommendations and begin implementing them within six months after submission, consulting stakeholders. Mechanism: FDA program implementation; no automatic product approval

Sec. 303(a)–(c) · Government Power — Requires FDA competitive-generic pathway study and implementation steps

(1) report the review, its findings, and any recommendations to committees of jurisdiction within 12 months of the date of the enactment of this Act; and

Sec. 303(a)–(c) · Economic Freedom — Requires FDA to review the competitive-generic-therapy pathway within 12 months, report recommendations and begin implementing them within six months after submission, consulting stakeholders. Mechanism: FDA program implementation; no automatic product approval

Sec. 303(a)–(c) · Government Power — Requires FDA competitive-generic pathway study and implementation steps

(2) not later than 6 months after transmitting the review to Congress, begin implementing the recommendations.

Sec. 303(a)–(c) · Economic Freedom — Requires FDA to review the competitive-generic-therapy pathway within 12 months, report recommendations and begin implementing them within six months after submission, consulting stakeholders. Mechanism: FDA program implementation; no automatic product approval

Sec. 303(a)–(c) · Government Power — Requires FDA competitive-generic pathway study and implementation steps

(c) Collaboration.--In carrying out this section, the Secretary shall incorporate the perspectives of health care stakeholders.

SEC. 304. BIOSIMILAR BIOLOGICAL PRODUCTS.

Sec. 304(a)(4)–(6), amended PHSA §351(k)(4), amended PHSA §351(k)(6) · Property Rights — Revises biosimilar interchangeability and preserves qualifying unexpired first-interchangeable exclusivity during transition; affects biologic applicants and exclusivity holders. Mechanism: FDA biologics licensure

Sec. 304(a)(1)–(6) · Economic Freedom — Removes the separate statutory interchangeability distinction and deems biosimilars interchangeable after a 60-day transition, subject to preserved exclusivity; revises related statutory language. Mechanism: FDA biologics licensing and substitution law

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(a) In General.--Section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)) is amended--

Sec. 304(a)(1)–(6) · Economic Freedom — Removes the separate statutory interchangeability distinction and deems biosimilars interchangeable after a 60-day transition, subject to preserved exclusivity; revises related statutory language. Mechanism: FDA biologics licensing and substitution law

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(1) in the subsection heading, by striking ``or Interchangeable'';

Sec. 304(a)(1)–(6) · Economic Freedom — Removes the separate statutory interchangeability distinction and deems biosimilars interchangeable after a 60-day transition, subject to preserved exclusivity; revises related statutory language. Mechanism: FDA biologics licensing and substitution law

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(2) in paragraph (2)-- (A) by striking subparagraph (B); (B) by redesignating clauses (ii) and (iii) of subparagraph (A) as subparagraphs (B) and (C), respectively, and adjusting the margins accordingly; (C) in subparagraph (A)-- (i) in clause (i), by redesignating subclauses (I) through (V) as clauses (i) through (v), respectively, and adjusting the margins accordingly; (ii) in clause (i), as so redesignated by clause (i) of this subparagraph, by redesignating items (aa) through (cc) as subclauses (I) through (III), respectively, and adjusting the margins accordingly; (iii) in subclause (II) of clause (i), as so redesignated by clause (ii) of this subparagraph, by striking ``item (aa) or (cc)'' and inserting ``subclause (I) or (III)''; and (iv) by striking ``(A) in general'' and all that follows through ``An application submitted under this subsection shall include information'' and inserting the following: ``(A) In general.--An application submitted under this subsection shall include information''; (D) in subparagraph (B), as so redesignated by subparagraph (B) of this paragraph, by striking ``clause (i)(I)'' and inserting ``subparagraph (A)(i)''; and (E) in subparagraph (C), as so redesignated by subparagraph (B) of this paragraph, by redesignating subclauses (I) through (III) as clauses (i) through (iii), respectively, and adjusting the margins accordingly;

Sec. 304(a)(1)–(6) · Economic Freedom — Removes the separate statutory interchangeability distinction and deems biosimilars interchangeable after a 60-day transition, subject to preserved exclusivity; revises related statutory language. Mechanism: FDA biologics licensing and substitution law

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(3) by amending subparagraph (A) of paragraph (3) to read as follows: ``(A) the Secretary determines that the information submitted in the application (or the supplement) is sufficient to show that the biological product is biosimilar to the reference product; and'';

Sec. 304(a)(4)–(6), amended PHSA §351(k)(4), amended PHSA §351(k)(6) · Property Rights — Revises biosimilar interchangeability and preserves qualifying unexpired first-interchangeable exclusivity during transition; affects biologic applicants and exclusivity holders. Mechanism: FDA biologics licensure

Sec. 304(a)(1)–(6) · Economic Freedom — Removes the separate statutory interchangeability distinction and deems biosimilars interchangeable after a 60-day transition, subject to preserved exclusivity; revises related statutory language. Mechanism: FDA biologics licensing and substitution law

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(4) by amending paragraph (4) to read as follows:
``(4) Interchangeability.-- ``(A) In general.--A biological product licensed under this subsection shall be deemed to be interchangeable with the reference product, subject to subparagraph (B). ``(B) Timing of deemed interchangeability.-- ``(i) Licensure on or after transition date.--A biological product licensed under this subsection on or after the transition date described in subparagraph (C) (in this clause referred to as the `applicable biological product') shall be deemed to be interchangeable with the reference product upon such licensure, unless the applicable biological product relied on the same reference product as another biological product for which-- ``(I) licensure under this subsection was in effect on the day before the date of enactment of the Faster Clinical Trials Act; and ``(II) a first interchangeable exclusivity period under paragraph (6) (as in effect on the day before the date of enactment of such Act) is in effect on the date of licensure of the applicable biological product, in which case the applicable biological product shall be deemed interchangeable with the reference product under this paragraph on the date on which the exclusivity period described in subclause (II) ends. ``(ii) Licensure prior to transition date.--A biological product licensed under this subsection prior to the transition date described in subparagraph (C) (referred to in this clause as the `applicable biological product') shall be deemed to be interchangeable with the reference product on such transition date, unless the applicable biological product relied on the same reference product as another biological product for which-- ``(I) licensure under this subsection was in effect on the day before the date of enactment of the Faster Clinical Trials Act; and ``(II) a first interchangeable exclusivity period under paragraph (6) (as in effect on the day before the date of enactment of such Act) is in effect on the transition date, in which case the applicable biological product shall be deemed interchangeable with the reference product under this paragraph on the date on which the exclusivity period described in subclause (II) ends. ``(C) Transition date.--The transition date described in this subparagraph is the date that is 60 days after the date of enactment of the Faster Clinical Trials Act.'';

Sec. 304(a)(4)–(6), amended PHSA §351(k)(4), amended PHSA §351(k)(6) · Property Rights — Revises biosimilar interchangeability and preserves qualifying unexpired first-interchangeable exclusivity during transition; affects biologic applicants and exclusivity holders. Mechanism: FDA biologics licensure

Sec. 304(a)(1)–(6) · Economic Freedom — Removes the separate statutory interchangeability distinction and deems biosimilars interchangeable after a 60-day transition, subject to preserved exclusivity; revises related statutory language. Mechanism: FDA biologics licensing and substitution law

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(5) by amending paragraph (6) to read as follows:
``(6) Transition with respect to preserving first interchangeable exclusivity with respect to certain biological products.--With respect to a biological product licensed under this subsection before the date of enactment of the Faster Clinical Trials Act, for which there was an unexpired period of first interchangeable exclusivity under this subsection (as then in effect), such unexpired exclusivity period shall remain in effect for the duration of such period.''; and

Sec. 304(a)(4)–(6), amended PHSA §351(k)(4), amended PHSA §351(k)(6) · Property Rights — Revises biosimilar interchangeability and preserves qualifying unexpired first-interchangeable exclusivity during transition; affects biologic applicants and exclusivity holders. Mechanism: FDA biologics licensure

Sec. 304(a)(1)–(6) · Economic Freedom — Removes the separate statutory interchangeability distinction and deems biosimilars interchangeable after a 60-day transition, subject to preserved exclusivity; revises related statutory language. Mechanism: FDA biologics licensing and substitution law

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(6) in paragraph (8)(D)-- (A) in clause (i), by striking ``class; and'' and inserting ``class.''; (B) by striking clause (ii); and (C) by striking ``description of--'' and all that follows through ``criteria that the Secretary'' and inserting ``description of the criteria that the Secretary''.

Sec. 304(b), amended FDCA §505B(m) · Economic Freedom — Adjusts pediatric-assessment treatment of biosimilars based on reference-product indications and available formulations. Mechanism: existing pediatric drug/biologics review

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(b) Conforming Amendments.--

Sec. 304(b), amended FDCA §505B(m) · Economic Freedom — Adjusts pediatric-assessment treatment of biosimilars based on reference-product indications and available formulations. Mechanism: existing pediatric drug/biologics review

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(1) Section 351(i)(3) of the Public Health Service Act (42 U.S.C. 262(i)(3)) is amended by striking ``that is shown to meet the standards described in subsection (k)(4)'' and inserting ``licensed under subsection (k)''.

Sec. 304(b), amended FDCA §505B(m) · Economic Freedom — Adjusts pediatric-assessment treatment of biosimilars based on reference-product indications and available formulations. Mechanism: existing pediatric drug/biologics review

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(2) Section 352A of the Public Health Service Act (42 U.S.C. 263-1) is amended by striking ``and interchangeable biosimilar biological products'' each place such term appears.

Sec. 304(b), amended FDCA §505B(m) · Economic Freedom — Adjusts pediatric-assessment treatment of biosimilars based on reference-product indications and available formulations. Mechanism: existing pediatric drug/biologics review

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(3) Section 744G(14) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j-51(14)) is amended by striking ``, including a supplement requesting that the Secretary determine that the biosimilar biological product meets the standards for interchangeability described in section 351(k)(4) of the Public Health Service Act''.

Sec. 304(b), amended FDCA §505B(m) · Economic Freedom — Adjusts pediatric-assessment treatment of biosimilars based on reference-product indications and available formulations. Mechanism: existing pediatric drug/biologics review

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(4) Section 505B(l) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(l)) is amended to read as follows:
``(l) Biosimilar Biological Products.--A biological product for which an application is submitted under section 351(k) of the Public Health Service Act shall be considered to have a new active ingredient for purposes of this section only if--
``(1) the application seeks licensure for a claimed indication-- ``(A) that has been approved for a relevant pediatric population; or ``(B) for which there is a deferral of a relevant pediatric assessment under subsection (a)(4) of this section for the reference product applicant; and
``(2) a pediatric assessment under this section would not involve the development of a biological product with a strength, dosage form, route of administration, and condition of use for which there would not be a reference product.''.

Sec. 304(c)(1)–(3), (d)(1)–(2) · Economic Freedom — Requires biosimilar/interchangeability guidance updates within 18 months and follow-up after comments; preserves biosimilarity licensing standard and FDA evidence authority. Mechanism: FDA guidance/licensure

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(c) Guidance.--The Secretary shall--

Sec. 304(c)(1)–(3), (d)(1)–(2) · Economic Freedom — Requires biosimilar/interchangeability guidance updates within 18 months and follow-up after comments; preserves biosimilarity licensing standard and FDA evidence authority. Mechanism: FDA guidance/licensure

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(1) not later than 18 months after the date of enactment of this Act, update existing draft and final guidance to reflect the amendments made by this section, including by revising or revoking the guidance entitled ``Considerations in Demonstrating Interchangeability With a Reference Product'' (May 2019) and ``Considerations in Demonstrating Interchangeability With a Reference Product: Update'' (June 2024);

Sec. 304(c)(1)–(3), (d)(1)–(2) · Economic Freedom — Requires biosimilar/interchangeability guidance updates within 18 months and follow-up after comments; preserves biosimilarity licensing standard and FDA evidence authority. Mechanism: FDA guidance/licensure

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(2) not later than 18 months after the date of enactment of this Act, issue or revise guidance on review and approval of biosimilar biological products under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)) relating to the data and information that an applicant is required to submit to support a determination that a biosimilar biological product that is the subject of an application under such section is biosimilar to the reference product (as defined in section 351(i) of such Act (42 U.S.C. 262(i))); and

Sec. 304(c)(1)–(3), (d)(1)–(2) · Economic Freedom — Requires biosimilar/interchangeability guidance updates within 18 months and follow-up after comments; preserves biosimilarity licensing standard and FDA evidence authority. Mechanism: FDA guidance/licensure

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(3) not later than 18 months after the comment period closes on the guidance under paragraphs (1) and (2), issue revised draft or final versions of such guidance.

Sec. 304(c)(1)–(3), (d)(1)–(2) · Economic Freedom — Requires biosimilar/interchangeability guidance updates within 18 months and follow-up after comments; preserves biosimilarity licensing standard and FDA evidence authority. Mechanism: FDA guidance/licensure

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(d) Rule of Construction.--The amendments made by this section shall not be construed--

Sec. 304(c)(1)–(3), (d)(1)–(2) · Economic Freedom — Requires biosimilar/interchangeability guidance updates within 18 months and follow-up after comments; preserves biosimilarity licensing standard and FDA evidence authority. Mechanism: FDA guidance/licensure

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(1) to alter the standard or the information required for licensure of a biological product as biosimilar to a reference product pursuant to section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)); or

Sec. 304(c)(1)–(3), (d)(1)–(2) · Economic Freedom — Requires biosimilar/interchangeability guidance updates within 18 months and follow-up after comments; preserves biosimilarity licensing standard and FDA evidence authority. Mechanism: FDA guidance/licensure

Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance

(2) to limit the information that may be required by the Secretary to support the licensure of a biological product as biosimilar to a reference product pursuant to such section.

SEC. 305. CERTIFICATION OF PATENT INFORMATION IN CERTAIN APPLICATIONS FOR BIOLOGICAL PRODUCTS.

Sec. 305, new PHSA §351(o)(1)(A)(i)–(iv), (B) · Property Rights — Requires specified biologic applications relying on covered third-party investigations to certify each covered patent as unfiled, expired, expiring on a stated date, or invalid/noninfringed, and to distinguish irrelevant method-of-use patents. Affected: applicants and patent holders. Mechanism: FDA application completeness and existing patent procedures; no new infringement damages specified

Sec. 305, new §351(o)(2)(A)–(B) · Property Rights — Limits certifications to defined covered investigations and patents, including third-party studies used without a right of reference. Mechanism: statutory application scope

Sec. 305, new §351(o)(1)–(2) · Economic Freedom — Adds patent certifications and method-of-use statements to qualifying biologics applications. Mechanism: FDA application review

Sec. 305, new §351(o)(1)(A)–(B) · Privacy and Due Process — Requires applicants to make formal patent-status and noninfringement assertions; their legal significance depends on incorporated biologics and patent procedures. Mechanism: FDA application requirements

Sec. 305, new §351(o)(1)–(2) · Government Power — Adds patent-information certification requirements to covered biologic applications

Section 351 of the Public Health Service Act (42 U.S.C. 262) is amended by adding at the end the following:

Sec. 305, new PHSA §351(o)(1)(A)(i)–(iv), (B) · Property Rights — Requires specified biologic applications relying on covered third-party investigations to certify each covered patent as unfiled, expired, expiring on a stated date, or invalid/noninfringed, and to distinguish irrelevant method-of-use patents. Affected: applicants and patent holders. Mechanism: FDA application completeness and existing patent procedures; no new infringement damages specified

Sec. 305, new §351(o)(2)(A)–(B) · Property Rights — Limits certifications to defined covered investigations and patents, including third-party studies used without a right of reference. Mechanism: statutory application scope

Sec. 305, new §351(o)(1)–(2) · Economic Freedom — Adds patent certifications and method-of-use statements to qualifying biologics applications. Mechanism: FDA application review

Sec. 305, new §351(o)(1)(A)–(B) · Privacy and Due Process — Requires applicants to make formal patent-status and noninfringement assertions; their legal significance depends on incorporated biologics and patent procedures. Mechanism: FDA application requirements

Sec. 305, new §351(o)(1)–(2) · Government Power — Adds patent-information certification requirements to covered biologic applications

``(o) Certification of Patent Information in Certain Applications.--

Sec. 305, new PHSA §351(o)(1)(A)(i)–(iv), (B) · Property Rights — Requires specified biologic applications relying on covered third-party investigations to certify each covered patent as unfiled, expired, expiring on a stated date, or invalid/noninfringed, and to distinguish irrelevant method-of-use patents. Affected: applicants and patent holders. Mechanism: FDA application completeness and existing patent procedures; no new infringement damages specified

Sec. 305, new §351(o)(2)(A)–(B) · Property Rights — Limits certifications to defined covered investigations and patents, including third-party studies used without a right of reference. Mechanism: statutory application scope

Sec. 305, new §351(o)(1)–(2) · Economic Freedom — Adds patent certifications and method-of-use statements to qualifying biologics applications. Mechanism: FDA application review

Sec. 305, new §351(o)(1)(A)–(B) · Privacy and Due Process — Requires applicants to make formal patent-status and noninfringement assertions; their legal significance depends on incorporated biologics and patent procedures. Mechanism: FDA application requirements

Sec. 305, new §351(o)(1)–(2) · Government Power — Adds patent-information certification requirements to covered biologic applications

``(1) In general.--An application submitted under this section for a biological product that includes a full report of a covered investigation shall also include-- ``(A) a certification, in the opinion of the applicant and to the best of their knowledge, with respect to each covered patent-- ``(i) that such patent information has not been filed; ``(ii) that such patent has expired; ``(iii) of the date on which such patent will expire; or ``(iv) that such patent is invalid or will not be infringed by the manufacture, use, or sale of such product for which the application is submitted; and ``(B) if information was filed under subsection (l) for a method of use patent which does not claim a use for which the applicant is seeking approval under this section, a statement that the method of use patent does not claim such a use.

Sec. 305, new PHSA §351(o)(1)(A)(i)–(iv), (B) · Property Rights — Requires specified biologic applications relying on covered third-party investigations to certify each covered patent as unfiled, expired, expiring on a stated date, or invalid/noninfringed, and to distinguish irrelevant method-of-use patents. Affected: applicants and patent holders. Mechanism: FDA application completeness and existing patent procedures; no new infringement damages specified

Sec. 305, new §351(o)(2)(A)–(B) · Property Rights — Limits certifications to defined covered investigations and patents, including third-party studies used without a right of reference. Mechanism: statutory application scope

Sec. 305, new §351(o)(1)–(2) · Economic Freedom — Adds patent certifications and method-of-use statements to qualifying biologics applications. Mechanism: FDA application review

Sec. 305, new §351(o)(1)(A)–(B) · Privacy and Due Process — Requires applicants to make formal patent-status and noninfringement assertions; their legal significance depends on incorporated biologics and patent procedures. Mechanism: FDA application requirements

Sec. 305, new §351(o)(1)–(2) · Government Power — Adds patent-information certification requirements to covered biologic applications

``(2) Definitions.--In this subsection: ``(A) Covered investigation.--The term `covered investigation' means, with respect to a biological product for which an applicant submitted an application under this section, an investigation of such product that-- ``(i) was conducted to demonstrate whether such product is safe for use and is effective in use; ``(ii) was not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigation was conducted; and ``(iii) is relied upon by the applicant seeking approval of such application. ``(B) Covered patent.--The term `covered patent' means a patent-- ``(i) which claims-- ``(I) the biological product for which a covered investigation was conducted; or ``(II) a use for such product for which an applicant is seeking approval of an application under this section; and ``(ii) for which information is required to be filed under subsection (l).''.

SEC. 306. GAO REPORT.

Not later than 3 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to Congress a report evaluating--

Sec. 306(1)–(5) · Privacy and Due Process — Requires GAO review within three years of FDA process reforms, user-fee pilots and rare-disease effects; no individual hearing or penalty

Sec. 306(1)–(5) · Government Power — Requires GAO report within three years

(1) any progress in implementing section 301 during the period covered by the report;

Sec. 306(1)–(5) · Privacy and Due Process — Requires GAO review within three years of FDA process reforms, user-fee pilots and rare-disease effects; no individual hearing or penalty

Sec. 306(1)–(5) · Government Power — Requires GAO report within three years

(2) dissemination by the Food and Drug Administration of resources related to developing a drug;

Sec. 306(1)–(5) · Privacy and Due Process — Requires GAO review within three years of FDA process reforms, user-fee pilots and rare-disease effects; no individual hearing or penalty

Sec. 306(1)–(5) · Government Power — Requires GAO report within three years

(3) implementation by the Secretary of pilot programs using fees made available pursuant to subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379f et seq.), such as the Split Real Time Application Review pilot program, the Model-Informed Drug Development Paired Meeting Program, and the Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program;

Sec. 306(1)–(5) · Privacy and Due Process — Requires GAO review within three years of FDA process reforms, user-fee pilots and rare-disease effects; no individual hearing or penalty

Sec. 306(1)–(5) · Government Power — Requires GAO report within three years

(4) implementation by the Secretary of each program established by this Act or an amendment made by this Act to improve clinical trial efficiency and ensure regulatory consistency; and

Sec. 306(1)–(5) · Privacy and Due Process — Requires GAO review within three years of FDA process reforms, user-fee pilots and rare-disease effects; no individual hearing or penalty

Sec. 306(1)–(5) · Government Power — Requires GAO report within three years

(5) whether implementing each such program has had a beneficial impact on the development of a medical product for a rare disease or condition, including a rare cancer.

SEC. 307. DEFINITIONS.

In this Act:

Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties

(1) Clinical investigation.--The term ``clinical investigation'' has the meaning given such term in section 50.3 of title 21, Code of Federal Regulations (or any successor regulation).

Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties

(2) Department.--The term ``Department'' means the Department of Health and Human Services.

Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties

(3) Good clinical practice.--The term ``good clinical practice'' means the standard, entitled ``Good Clinical Practice'', maintained by the International Council for Harmonisation and implemented by the Secretary.

Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties

(4) Institutional review board.--The term ``institutional review board'' has the meaning given such term in section 56.102 of title 21, Code of Federal Regulations (or any successor regulation).

Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties

(5) Investigational new drug application.--The term ``investigational new drug application'' means an application submitted pursuant to part 312 of title 21, Code of Federal Regulations (or any successor regulation), for an investigational new drug (as defined in section 312.3 of such part).

Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties

(6) Medical product.--The term ``medical product'' means--

Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties

(A) a drug or device, as defined in section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321); or

Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties

(B) a biological product, as defined in section 351 of the Public Health Service Act (42 U.S.C. 262).

Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties

(7) Rare disease or condition.--The term ``rare disease or condition'' has the meaning given such term in section 526(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb(a)).

Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties

(8) Routine point-of-care clinical trial.--The term ``routine point-of-care clinical trial'' means a clinical investigation of a medical product that--

Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties

(A) is integrated into clinical practice, including routine in-person, or virtual, visits;

Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties

(B) includes health providers as investigators;

Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties

(C) may be conducted in a primary care setting, an outpatient care setting, the home of a patient participating in such investigation, or a similar location; and

Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties

(D) may follow a streamlined protocol and procedures focused on essential data collection generating or incorporating real-world data from an electronic or other health record.

Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties

(9) Secretary.--The term ``Secretary'' means the Secretary of Health and Human Services. TITLE IV--PRECISION ONCOLOGY MODERNIZATION

SEC. 401. FINDINGS AND PURPOSE.

Sec. 401 — consists of nonoperative findings/purpose and is not independently scored. Each item below identifies its affected parties and enforcement mechanism. Where a provision only directs an agency to study, issue guidance, or report, no new private penalty is created by that provision. Existing FDA approval, inspection, human-subject protections, Medicare payment, and federal award conditions apply where indicated

Sec. 401(a)–(b) · Government Power — Legislative findings/purpose only; no independently operative obligation

(a) Findings.--Congress finds the following:

Sec. 401 — consists of nonoperative findings/purpose and is not independently scored. Each item below identifies its affected parties and enforcement mechanism. Where a provision only directs an agency to study, issue guidance, or report, no new private penalty is created by that provision. Existing FDA approval, inspection, human-subject protections, Medicare payment, and federal award conditions apply where indicated

Sec. 401(a)–(b) · Government Power — Legislative findings/purpose only; no independently operative obligation

(1) Advances in molecular oncology have enabled the identification of specific genetic alterations that drive certain cancers, enabling the development of targeted therapies with high efficacy in defined patient populations.

Sec. 401 — consists of nonoperative findings/purpose and is not independently scored. Each item below identifies its affected parties and enforcement mechanism. Where a provision only directs an agency to study, issue guidance, or report, no new private penalty is created by that provision. Existing FDA approval, inspection, human-subject protections, Medicare payment, and federal award conditions apply where indicated

Sec. 401(a)–(b) · Government Power — Legislative findings/purpose only; no independently operative obligation

(2) Approved oncology drug labels frequently reflect clinical trial populations that predate the routine use of genomic profiling and may not adequately reflect current scientific understanding of patient subpopulations for whom a given therapy is inappropriate.

Sec. 401 — consists of nonoperative findings/purpose and is not independently scored. Each item below identifies its affected parties and enforcement mechanism. Where a provision only directs an agency to study, issue guidance, or report, no new private penalty is created by that provision. Existing FDA approval, inspection, human-subject protections, Medicare payment, and federal award conditions apply where indicated

Sec. 401(a)–(b) · Government Power — Legislative findings/purpose only; no independently operative obligation

(3) Outdated labeling can contribute to suboptimal treatment sequencing, unnecessary toxicity, and foregone opportunity for patients to receive a more precisely and effective targeted treatment option.

Sec. 401 — consists of nonoperative findings/purpose and is not independently scored. Each item below identifies its affected parties and enforcement mechanism. Where a provision only directs an agency to study, issue guidance, or report, no new private penalty is created by that provision. Existing FDA approval, inspection, human-subject protections, Medicare payment, and federal award conditions apply where indicated

Sec. 401(a)–(b) · Government Power — Legislative findings/purpose only; no independently operative obligation

(4) The Food and Drug Administration's Project Renewal initiative, established to modernize drug product labeling to reflect contemporary scientific and clinical knowledge, provides a foundation that can be expanded to systematically address genomic exclusions in oncology drug labels.

Sec. 401 — consists of nonoperative findings/purpose and is not independently scored. Each item below identifies its affected parties and enforcement mechanism. Where a provision only directs an agency to study, issue guidance, or report, no new private penalty is created by that provision. Existing FDA approval, inspection, human-subject protections, Medicare payment, and federal award conditions apply where indicated

Sec. 401(a)–(b) · Government Power — Legislative findings/purpose only; no independently operative obligation

(5) A formal, science-driven process for incorporating genomic exclusion criteria into oncology labeling would promote precision medicine, improve patient outcomes, and advance the efficient use of health care resources.

Sec. 401 — consists of nonoperative findings/purpose and is not independently scored. Each item below identifies its affected parties and enforcement mechanism. Where a provision only directs an agency to study, issue guidance, or report, no new private penalty is created by that provision. Existing FDA approval, inspection, human-subject protections, Medicare payment, and federal award conditions apply where indicated

Sec. 401(a)–(b) · Government Power — Legislative findings/purpose only; no independently operative obligation

(b) Purpose.--To establish a process for reviewing and updating the labeling of approved oncology drugs to reflect genetically defined patient subpopulations.

SEC. 402. ONCOLOGY CENTER OF EXCELLENCE.

Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration

Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031

(a) In General.--The Secretary shall establish the Food and Drug Administration Oncology Center of Excellence as an Intercenter Institute described in section 1014 to promote development and facilitate the review of medical products intended to diagnose and treat oncologic and hematologic malignancies, including--

Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration

Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031

(1) cancers in infants, children, and adolescents; and

Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration

Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031

(2) rare cancers.

Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration

Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031

(b) Activities.--In addition to the activities of an Intercenter Institute described in section 1014, the Oncology Center of Excellence shall--

Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration

Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031

(1) sponsor or conduct projects to advance the development and regulation of medical products for patients with cancer, including-- (A) Project Orbis a collaborative framework to facilitate the concurrent submission and collaborative regulatory review of oncology products among international regulatory authorities to expedite global patient access to safe and effective cancer treatments; (B) Project Optimus a program to reform dose optimization and selection for oncologic therapies by encouraging multi-dose characterization early in clinical development; (C) Real-Time Oncology Review (RTOR) a voluntary pilot program for the early submission of data modules prior to the formal filing of a complete oncology marketing application to streamline regulatory review; (D) Project Confirm a public framework for the monitoring of confirmatory clinical trials required under the accelerated approval pathway for oncology indications to track the confirmation of clinical benefit; (E) Project Pragmatica a program to integrate pragmatic clinical trial designs into the evaluation of approved oncology medical products, utilizing streamlined eligibility criteria and real-world clinical practice settings to reduce operational burdens on patients and investigators; and (F) Project Renewal a program to assess information that may inform updates to the labeling of oncology drugs to incorporate genomic exclusion criteria;

Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration

Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031

(2) assist in addressing scientific, clinical, and policy issues related to the development and regulation of oncology and hematology products;

Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration

Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031

(3) award grants, cooperative agreements, or contracts, or enter into memoranda of understanding, and foster public- private partnerships or consortia to support the activities required under this section; and

Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration

Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031

(4) hold meetings and workshops to engage directly with-- (A) cancer patient organizations and families of patients with cancer; (B) developers of oncology and hematology products; and (C) researchers and specialty medical societies.

Sec. 402(c)(1)–(2) · Economic Freedom — Requires FY2027–2031 transfers of such sums as necessary from specified existing FDA, interagency and ARPA-H-related funds, plus presidential budget identification. Mechanism: agency fiscal transfers, not an unrestricted new appropriation

Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031

(c) Funding.--

Sec. 402(c)(1)–(2) · Economic Freedom — Requires FY2027–2031 transfers of such sums as necessary from specified existing FDA, interagency and ARPA-H-related funds, plus presidential budget identification. Mechanism: agency fiscal transfers, not an unrestricted new appropriation

Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031

(1) In general.--To carry out this section, the Secretary shall transfer to the Oncology Center of Excellence for each of fiscal years 2027 through 2031-- (A) such sums as necessary from the amounts made available in the FDA Innovation Account under section 1002(b)(2)(A) of the 21st Century Cures Act (Public Law 114-255); (B) such sums as necessary from amounts made available pursuant to interagency transfers and agreements, including with the National Cancer Institute, as authorized under 31 U.S.C. 1535; and (C) such sums as necessary from the amounts made available to carry out section 499A(f) of such Act (42 U.S.C. 290c(f)), related to cooperation of the Advanced Research Projects Agency-Health with the Food and Drug Administration to facilitate the development of medical products and projects that are the highest priorities to the Advanced Research Projects Agency-Health.

Sec. 402(c)(1)–(2) · Economic Freedom — Requires FY2027–2031 transfers of such sums as necessary from specified existing FDA, interagency and ARPA-H-related funds, plus presidential budget identification. Mechanism: agency fiscal transfers, not an unrestricted new appropriation

Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031

(2) Budget clarification.--Any budget request of the President shall specify an amount for carrying out this section.

SEC. 403. LABELING REVISIONS FOR GENOMIC EXCLUSIONS IN ONCOLOGY DRUGS.

Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section

Sec. 403(a), (b)(1)–(2) · Economic Freedom — Requires a genomic-exclusion labeling assessment program within 12 months, identification of eligible oncology drugs and evidence channels, standardized language, voluntary supplements and agency updates where supported. Mechanism: FDA labeling process

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(a) In General.--Not later than 12 months after the date of enactment of this Act, the Secretary shall establish, acting through the Food and Drug Administration Oncology Center of Excellence (hereinafter referred to as the ``Center''), a program to assess information that may inform updates to the labeling of approved oncology drugs to incorporate genomic exclusion criteria (hereinafter referred to as the ``Program'').

Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section

Sec. 403(b)(2)(C), (h)(1)–(2) · Property Rights — Encourages voluntary sponsor labeling supplements and preserves existing drug approval status except authorized label updates; does not independently transfer patent rights. Mechanism: FDA labeling law

Sec. 403(a), (b)(1)–(2) · Economic Freedom — Requires a genomic-exclusion labeling assessment program within 12 months, identification of eligible oncology drugs and evidence channels, standardized language, voluntary supplements and agency updates where supported. Mechanism: FDA labeling process

Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(b) Duties.--In carrying out the Program, the Center shall--

Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section

Sec. 403(a), (b)(1)–(2) · Economic Freedom — Requires a genomic-exclusion labeling assessment program within 12 months, identification of eligible oncology drugs and evidence channels, standardized language, voluntary supplements and agency updates where supported. Mechanism: FDA labeling process

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(1) identify oncology drugs approved under 505(b) or 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b) or (j)), or licensed under section 351 of the Public Health Service Act (42 U.S.C. 262) for which-- (A) there is new scientific evidence available pertaining to one or more actionable genetic alterations that is not reflected in the approved labeling of such drugs; and (B) the updating of such approved labeling would benefit the public health; and

Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section

Sec. 403(b)(2)(C), (h)(1)–(2) · Property Rights — Encourages voluntary sponsor labeling supplements and preserves existing drug approval status except authorized label updates; does not independently transfer patent rights. Mechanism: FDA labeling law

Sec. 403(a), (b)(1)–(2) · Economic Freedom — Requires a genomic-exclusion labeling assessment program within 12 months, identification of eligible oncology drugs and evidence channels, standardized language, voluntary supplements and agency updates where supported. Mechanism: FDA labeling process

Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(2) establish a process to-- (A) identify such drugs, including-- (i) the procedures authorized under section 503D(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353d(b)), to receive clinical evidence on the impact of actionable genetic alterations on patient outcomes; and (ii) engagement through meetings and workshops authorized under section 3(b)(4) with-- (I) holders of approved oncology drug applications and other drug sponsors; (II) the Food and Drug Administation Rare Disease Innovation Hub; (III) the National Cancer Institute; and (IV) patient advocacy organizations, oncology professional societies, diagnostic test developers, and other relevant stakeholders; (B) develop standardized language for genomic exclusion criteria to support clear statements regarding the additional, modified, or supplemental information for amended oncology drug labeling; (C) encourage holders of approved oncology drug applications to submit voluntary labeling supplements to incorporate genomic exclusion criteria, including as supplemental applications described in sections 314.70 and 601.12 of title 21, Code of Federal Regulations (or any successor regulations); and (D) initiate labeling changes to incorporate genomic exclusion criteria, including under section 505(o) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(o)) and in a manner consistent with the requirements of section 503D(f)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353D(f)(2)).

Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section

Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers

Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(c) Selection of Oncology Drugs.--The Center shall identify oncology drugs under this section--

Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section

Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers

Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(1) based on factors including-- (A) the strength and consistency of clinical evidence supporting the impact of the action genetic alteration on patient outcomes; (B) the availability of one or more approved targeted oncology therapies addressing the relevant actionable genetic alteration or oncogenic driver; (C) the prevalence of the relevant genetic alteration or oncogenic driver in the indicated patient population; and (D) the potential clinical impact of failing to identify and exclude patients with the relevant alteration;

Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section

Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers

Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(2) on the basis of the available scientific evidence for incorporating genomic exclusion criteria into oncology drug labeling that meets the standards under section 505 for adding or modifying information to the labeling or providing supplemental information to the labeling regarding the use of the identified drug, including-- (A) data from randomized controlled trials demonstrating reduced effectiveness or safety changes of approved oncology products for patients with specific actionable genetic alterations; (B) prospective or retrospective biomarker analyses from adequate and well-controlled studies; (C) real-world evidence; and (D) mechanistic or preclinical evidence in conjunction with clinical data, where appropriate; and

Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section

Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers

Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(3) with consideration given to-- (A) whether a companion diagnostic test approved or cleared under section 515 or section 510(k) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360e and 21 U.S.C. 360(k)) respectively, or a laboratory developed test, is necessary to identify patients with a relevant actionable genetic alteration prior to seeking or initiating a labeling change to incorporate a genomic exclusion criterion into labeling under subsection (b); (B) promoting alignment, in coordination with the Center for Devices and Radiological Health, as appropriate, between revised oncology drug labeling under this section and the labeling of approved or cleared companion diagnostics; and (C) utilization of genomic profiling under next- generation sequencing or other multi-gene testing as a basis for identifying patients subject to a genomic exclusion criterion.

Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers

Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(d) Expedited Review for Labeling Supplements.--Labeling supplements to incorporate genomic exclusion criteria submitted pursuant to 505(xx) or 505(o)(4) shall--

Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers

Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(1) be exempt from user fees under the Prescription Drug User Fee Act; and

Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers

Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(2) be reviewed and acted upon no later than 180 days after submission of a complete supplement. Nothing in this subsection shall be constructed to limit the processes outlined in 505(o)(4).

Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers

Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(e) Transparency and Public Access.--The Secretary shall--

Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers

Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(1) maintain and make publicly available on the Food and Drug Administration's website a registry of oncology drug labels updated under the Program, and the evidence basis for each genomic exclusion determination; and

Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers

Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(2) publish, not less frequently than annually, a report summarizing Program activities, labeling updates completed, supplements received and acted upon, and any anticipated genetic alterations under consideration for the following year;

Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers

Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(f) Guidance.--Within 180 days of enactment of the Precision Oncology Modernization Act, the Secretary shall issue draft guidance on the actions described in subsection (b), standards in subsection (c), and role of the CDRH outlined in subsection (d). The guidance shall be finalized no later than 2 years after enactment.

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(g) Report to Congress.--Not later than 3 years after the date of enactment of this Act, and every 2 years thereafter, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report that includes--

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(1) a description of the activities carried out under the Program, including the number of oncology drug labels reviewed, updated, or pending update;

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(2) the number of voluntary labeling supplements received and acted upon under the Program;

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(3) an assessment of challenges and barriers encountered in implementing the Program, including any scientific, legal, or operational barriers;

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(4) recommendations for legislative or regulatory changes that would improve the Program or accelerate the incorporation of genomic exclusion criteria into oncology drug labeling; and

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(5) an analysis of the potential impact of Program activities on patient outcomes, treatment sequencing, and access to targeted oncology therapies.

Sec. 403(b)(2)(C), (h)(1)–(2) · Property Rights — Encourages voluntary sponsor labeling supplements and preserves existing drug approval status except authorized label updates; does not independently transfer patent rights. Mechanism: FDA labeling law

Sec. 403(h)(1)–(2), (i)(1)–(3) · Privacy and Due Process — Preserves other FDA labeling authority and existing approvals except label updates; defines actionable genetic alteration, targeted therapy and genomic exclusion. Mechanism: existing FDA procedures

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(h) Rule of Construction.--Nothing in this Act shall be construed--

Sec. 403(b)(2)(C), (h)(1)–(2) · Property Rights — Encourages voluntary sponsor labeling supplements and preserves existing drug approval status except authorized label updates; does not independently transfer patent rights. Mechanism: FDA labeling law

Sec. 403(h)(1)–(2), (i)(1)–(3) · Privacy and Due Process — Preserves other FDA labeling authority and existing approvals except label updates; defines actionable genetic alteration, targeted therapy and genomic exclusion. Mechanism: existing FDA procedures

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(1) to limit the authority of the Secretary to require labeling changes for approved drugs under any other provision of the Federal Food, Drug, and Cosmetic Act or the Public Health Service Act; and

Sec. 403(b)(2)(C), (h)(1)–(2) · Property Rights — Encourages voluntary sponsor labeling supplements and preserves existing drug approval status except authorized label updates; does not independently transfer patent rights. Mechanism: FDA labeling law

Sec. 403(h)(1)–(2), (i)(1)–(3) · Privacy and Due Process — Preserves other FDA labeling authority and existing approvals except label updates; defines actionable genetic alteration, targeted therapy and genomic exclusion. Mechanism: existing FDA procedures

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(2) to affect the approval status of any oncology drug or biological product approved before the date of enactment of this Act except with respect to labeling updates made pursuant to the Program. The rules of construction under section 503D(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353d(b)) shall be deemed to apply to this section.

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(i) Definitions.--In this Act:

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(1) Actionable genetic alteration.--The term ``actionable genetic alteration'' means a somatic or germline mutation, gene fusion, copy number variation, or other molecular aberration in a patient's tumor or germline that has been demonstrated through clinical evidence to predict a meaningful difference in response or resistance that impacts the safety or efficacy of a drug or biological product intended to treat cancer.

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(2) Approved targeted oncology therapy.--The term ``approved targeted oncology therapy'' means a drug or biological product approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or section 351 of the Public Health Service Act (42 U.S.C. 262) for the treatment of a cancer defined in whole or in part by the presence of a specific genetic alteration.

Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers

(3) Genomic exclusion criterion.--The term ``genomic exclusion criterion'' means a labeling statement specifying that a drug is not indicated for, or should not be used in, patients whose tumors harbor a specific actionable genetic alteration for which an alternative approved targeted oncology therapy exists. TITLE V--AMERICAN FRONTIER BIOBANK

SEC. 501. ESTABLISHMENT OF THE AMERICAN FRONTIER BIOBANK.

Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment

Sec. 501(a), new §404P(b)(1)–(2) · Property Rights — Transfers existing All of Us program authorities, appropriations, personnel, data, specimens and infrastructure to the new federal Biobank; no compulsory private property taking is specified. Mechanism: NIH internal transition and existing award law

Sec. 501(a), new §404P(d)(1), new §404P(d)(4), new §404P(d)(11) · Economic Freedom — Requires nationwide corporate/nonprofit awards and data-sharing agreements and permits public/private financing to collect/analyze specimens and clinical data. Affected: research institutions and contractors. Mechanism: federal contracts and awards

Sec. 501(a), new §404P(i) · Economic Freedom — Authorizes $500 million for FY2027 and each subsequent fiscal year, available until expended; no statutory end date. This is an authorization, not an automatic appropriation

Sec. 501(a), new §404P(d)(1)–(2) · Privacy and Due Process — Authorizes collection/storage of biospecimens, longitudinal molecular/clinical data and electronic health records, with a target cohort of at least 3% of the population. Mechanism: NIH agreements and existing consent/privacy law

Sec. 501(a), new §404P(d)(3)–(4) · Privacy and Due Process — Requires mutually agreed tribal participation and data-sharing agreements with private/nonprofit partners to recruit, enroll and obtain informed consent. Mechanism: consultation and contractual oversight

Sec. 501(a), new §404P(d)(5)–(7) · Privacy and Due Process — Requires trial recruitment using Biobank data, sharing deidentified data with all registered researchers and incorporating NIH/VA datasets including All of Us and Million Veteran Program. Mechanism: NIH researcher registration, agreements and privacy law

Sec. 501(a), new §404P(d)(8)–(10), (f) · Privacy and Due Process — Authorizes integrated genomic/proteomic/metabolomic and health-record data, repeat sampling, continuous data integration, federated AI-ready systems and linked environmental/life-course data. Mechanism: NIH program controls; reidentification risk and specific access safeguards depend on implementation

Sec. 501(a), new §404P(g)(1)(A)–(B), (g)(2) · Privacy and Due Process — Requires informed consent or authorized-representative permission and at least existing federal/state privacy protections for biospecimens and associated clinical/demographic data. Mechanism: incorporated human-subject/privacy laws and NIH oversight; no independent new statutory damages remedy

Sec. 501(a), new §404P(a)–(c) · Government Power — Creates the American Frontier Biobank under NIH, transfers All of Us authorities, budget, staff and infrastructure within six months, and creates an NIH-appointed Administrator

Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board

Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives

Sec. 501(a), new §404P(f)–(g) · Government Power — Permits multimodal data linkage and requires consent and privacy compliance

Sec. 501(a), new §404P(h)–(i) · Government Power — Requires annual congressional notification beginning one year after enactment and authorizes $500 million in FY2027 and every later fiscal year, without an express sunset

Sec. 501(a), Sec. 404P(i) · Government Power — most other agency study, guidance and grant provisions create no new standalone criminal penalty. Appropriation authorizations are not assumed to have been funded. The five titles contain no general sunset; the FY2027–2031 limits on some authorities do not sunset the permanent Biobank authorization

Sec. 501(a), Sec. 404P(d)(5)–(10) · Government Power — notwithstanding explicit consent safeguards

(a) In General.--Part A of title IV of the Public Health Service Act (42 U.S.C. 281et seq.) is amended by adding at the end following: ``SEC. 404P. AMERICAN FRONTIER BIOBANK.

Sec. 501(a), new §404P(a)–(c) · Government Power — Creates the American Frontier Biobank under NIH, transfers All of Us authorities, budget, staff and infrastructure within six months, and creates an NIH-appointed Administrator

``(a) In General.--Pursuant to section 498E, the Director of NIH shall carry out a program to be known as the `American Frontier Biobank Program' (referred to in this section as the `Biobank Program'), which shall expand upon the work of the All of Us Research Program.

Sec. 501(a), new §404P(b)(1)–(2) · Property Rights — Transfers existing All of Us program authorities, appropriations, personnel, data, specimens and infrastructure to the new federal Biobank; no compulsory private property taking is specified. Mechanism: NIH internal transition and existing award law

Sec. 501(a), new §404P(a)–(c) · Government Power — Creates the American Frontier Biobank under NIH, transfers All of Us authorities, budget, staff and infrastructure within six months, and creates an NIH-appointed Administrator

``(b) Transition.--Not later than 6 months after the date of the enactment of this section, the Director of NIH shall--

Sec. 501(a), new §404P(b)(1)–(2) · Property Rights — Transfers existing All of Us program authorities, appropriations, personnel, data, specimens and infrastructure to the new federal Biobank; no compulsory private property taking is specified. Mechanism: NIH internal transition and existing award law

Sec. 501(a), new §404P(a)–(c) · Government Power — Creates the American Frontier Biobank under NIH, transfers All of Us authorities, budget, staff and infrastructure within six months, and creates an NIH-appointed Administrator

``(1) transfer to the Biobank Program, the authorities (including all budget authorities, available appropriations, and personnel), duties, obligations, and related legal and administrative functions, and the existing cohort, data, computational infrastructure, and biobanking capabilities of the All of Us Research Program; and

Sec. 501(a), new §404P(b)(1)–(2) · Property Rights — Transfers existing All of Us program authorities, appropriations, personnel, data, specimens and infrastructure to the new federal Biobank; no compulsory private property taking is specified. Mechanism: NIH internal transition and existing award law

Sec. 501(a), new §404P(a)–(c) · Government Power — Creates the American Frontier Biobank under NIH, transfers All of Us authorities, budget, staff and infrastructure within six months, and creates an NIH-appointed Administrator

``(2) provide for the orderly transition or realignment of awards made under, and capabilities of, the All of Us Research Program.

Sec. 501(a), new §404P(a)–(c) · Government Power — Creates the American Frontier Biobank under NIH, transfers All of Us authorities, budget, staff and infrastructure within six months, and creates an NIH-appointed Administrator

``(c) Administrator.--The Biobank Program shall be headed by an Administrator appointed by the Director of NIH. Such person shall be known and referred to as the American Frontier Biobank Administrator (in this section referred to as the `Administrator').

Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment

Sec. 501(a), new §404P(d)(1), new §404P(d)(4), new §404P(d)(11) · Economic Freedom — Requires nationwide corporate/nonprofit awards and data-sharing agreements and permits public/private financing to collect/analyze specimens and clinical data. Affected: research institutions and contractors. Mechanism: federal contracts and awards

Sec. 501(a), new §404P(d)(1)–(2) · Privacy and Due Process — Authorizes collection/storage of biospecimens, longitudinal molecular/clinical data and electronic health records, with a target cohort of at least 3% of the population. Mechanism: NIH agreements and existing consent/privacy law

Sec. 501(a), new §404P(d)(3)–(4) · Privacy and Due Process — Requires mutually agreed tribal participation and data-sharing agreements with private/nonprofit partners to recruit, enroll and obtain informed consent. Mechanism: consultation and contractual oversight

Sec. 501(a), new §404P(d)(5)–(7) · Privacy and Due Process — Requires trial recruitment using Biobank data, sharing deidentified data with all registered researchers and incorporating NIH/VA datasets including All of Us and Million Veteran Program. Mechanism: NIH researcher registration, agreements and privacy law

Sec. 501(a), new §404P(d)(8)–(10), (f) · Privacy and Due Process — Authorizes integrated genomic/proteomic/metabolomic and health-record data, repeat sampling, continuous data integration, federated AI-ready systems and linked environmental/life-course data. Mechanism: NIH program controls; reidentification risk and specific access safeguards depend on implementation

Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board

``(d) Program Elements.--In carrying out the Biobank Program, the Administrator shall--

Sec. 501(a), new §404P(d)(1), new §404P(d)(4), new §404P(d)(11) · Economic Freedom — Requires nationwide corporate/nonprofit awards and data-sharing agreements and permits public/private financing to collect/analyze specimens and clinical data. Affected: research institutions and contractors. Mechanism: federal contracts and awards

Sec. 501(a), new §404P(d)(1)–(2) · Privacy and Due Process — Authorizes collection/storage of biospecimens, longitudinal molecular/clinical data and electronic health records, with a target cohort of at least 3% of the population. Mechanism: NIH agreements and existing consent/privacy law

Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board

``(1) make awards to, or enter into contracts with, corporate entities or nonprofit entities across the United States to facilitate-- ``(A) the collection, storage, molecular data generation, and analysis of biological specimens, including longitudinal molecular and clinical data; and ``(B) with the support of artificial intelligence and other technologies, as appropriate, incorporating electronic health records of participants in accordance with subsection (c);

Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment

Sec. 501(a), new §404P(d)(1)–(2) · Privacy and Due Process — Authorizes collection/storage of biospecimens, longitudinal molecular/clinical data and electronic health records, with a target cohort of at least 3% of the population. Mechanism: NIH agreements and existing consent/privacy law

Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board

``(2) facilitate the recruitment of participants that are representative of at least 3 percent of the United States population, including representation of each State of the United States, the District of Columbia, each commonwealth, territory or possession of the United States, and each federally recognized Indian Tribe, with longitudinal data gathered in both urban and rural populations, including a pediatric cohort of participants;

Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment

Sec. 501(a), new §404P(d)(3)–(4) · Privacy and Due Process — Requires mutually agreed tribal participation and data-sharing agreements with private/nonprofit partners to recruit, enroll and obtain informed consent. Mechanism: consultation and contractual oversight

Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board

``(3) in facilitating the recruitment of participants under paragraph (2) who are members of a federally recognized Indian Tribe, work in partnership with Tribal nations, and through Tribal consultation, to establish mutually agreeable terms for Tribal participation, and operational processes and oversight, that respect Tribal sovereignty;

Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment

Sec. 501(a), new §404P(d)(1), new §404P(d)(4), new §404P(d)(11) · Economic Freedom — Requires nationwide corporate/nonprofit awards and data-sharing agreements and permits public/private financing to collect/analyze specimens and clinical data. Affected: research institutions and contractors. Mechanism: federal contracts and awards

Sec. 501(a), new §404P(d)(3)–(4) · Privacy and Due Process — Requires mutually agreed tribal participation and data-sharing agreements with private/nonprofit partners to recruit, enroll and obtain informed consent. Mechanism: consultation and contractual oversight

Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board

``(4) enter into data sharing agreements with private and nonprofit entities to build upon existing processes for the rapid, cost-effective, and scalable recruitment, and enrollment of, and obtaining informed consent from, participants for the collection of longitudinal data;

Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment

Sec. 501(a), new §404P(d)(5)–(7) · Privacy and Due Process — Requires trial recruitment using Biobank data, sharing deidentified data with all registered researchers and incorporating NIH/VA datasets including All of Us and Million Veteran Program. Mechanism: NIH researcher registration, agreements and privacy law

Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board

``(5) seek to enroll in clinical trials, using data in the Biobank, the individuals whose biological specimens are stored in the Biobank;

Sec. 501(a), new §404P(d)(5)–(7) · Privacy and Due Process — Requires trial recruitment using Biobank data, sharing deidentified data with all registered researchers and incorporating NIH/VA datasets including All of Us and Million Veteran Program. Mechanism: NIH researcher registration, agreements and privacy law

Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board

``(6) share deidentified data collected for the Biobank Program with all registered researchers;

Sec. 501(a), new §404P(d)(5)–(7) · Privacy and Due Process — Requires trial recruitment using Biobank data, sharing deidentified data with all registered researchers and incorporating NIH/VA datasets including All of Us and Million Veteran Program. Mechanism: NIH researcher registration, agreements and privacy law

Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board

``(7) incorporate existing data sources of the National Institutes of Health, and other relevant datasets (as determined by the Administrator) into research activities conducted through the Biobank Program, including data collected through the All of Us initiative and the Department of Veterans Affairs Millions Veterans Program;

Sec. 501(a), new §404P(d)(8)–(10), (f) · Privacy and Due Process — Authorizes integrated genomic/proteomic/metabolomic and health-record data, repeat sampling, continuous data integration, federated AI-ready systems and linked environmental/life-course data. Mechanism: NIH program controls; reidentification risk and specific access safeguards depend on implementation

Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board

``(8) generate and integrate multi-modal data, including genomic, proteomic, metabolomic, and other molecular data, with electronic health records and participant-reported information;

Sec. 501(a), new §404P(d)(8)–(10), (f) · Privacy and Due Process — Authorizes integrated genomic/proteomic/metabolomic and health-record data, repeat sampling, continuous data integration, federated AI-ready systems and linked environmental/life-course data. Mechanism: NIH program controls; reidentification risk and specific access safeguards depend on implementation

Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board

``(9) enable longitudinal participant data collection, including by conducting repeat sampling, engaging in continuous health data integration, and developing scalable research infrastructure to reduce the long-term costs of biomedical research and health care innovation;

Sec. 501(a), new §404P(d)(8)–(10), (f) · Privacy and Due Process — Authorizes integrated genomic/proteomic/metabolomic and health-record data, repeat sampling, continuous data integration, federated AI-ready systems and linked environmental/life-course data. Mechanism: NIH program controls; reidentification risk and specific access safeguards depend on implementation

Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board

``(10) support artificial intelligence-ready infrastructure, including secure, federated data systems that enable large-scale analysis while deidentifying patient data;

Sec. 501(a), new §404P(d)(1), new §404P(d)(4), new §404P(d)(11) · Economic Freedom — Requires nationwide corporate/nonprofit awards and data-sharing agreements and permits public/private financing to collect/analyze specimens and clinical data. Affected: research institutions and contractors. Mechanism: federal contracts and awards

Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board

``(11) facilitate the translation of research findings into clinical applications, including mechanisms for public and private funding to support Biobank Program activities; and

Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board

``(12) carry out all other activities as determined by the advisory board for the Biobank.

Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives

``(e) Advisory Board.--The Director of NIH shall establish a national advisory board to oversee the functions of the Biobank. The advisory board shall include representatives from--

Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives

``(1) the Institutes and Centers of the National Institutes of Health;

Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives

``(2) other relevant Federal agencies;

Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives

``(3) public and private research institutions, including entities that performed key participant and community engagement, genomic sequencing, and data security functions of the All of Us Research Program;

Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives

``(4) health care systems;

Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives

``(5) artificial intelligence and data experts;

Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives

``(6) clinical trial design experts;

Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives

``(7) pharmaceutical, biologic, and medical technology companies; and

Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives

``(8) experts in the ethical, legal, and social implications of science and technology.

Sec. 501(a), new §404P(d)(8)–(10), (f) · Privacy and Due Process — Authorizes integrated genomic/proteomic/metabolomic and health-record data, repeat sampling, continuous data integration, federated AI-ready systems and linked environmental/life-course data. Mechanism: NIH program controls; reidentification risk and specific access safeguards depend on implementation

Sec. 501(a), new §404P(f)–(g) · Government Power — Permits multimodal data linkage and requires consent and privacy compliance

``(f) Multi-Modal Data.--The data described in subsection (c)(7) may link biological, clinical, environmental, and other data, including information related to environmental exposures and factors identified using a life course approach.

Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment

Sec. 501(a), new §404P(g)(1)(A)–(B), (g)(2) · Privacy and Due Process — Requires informed consent or authorized-representative permission and at least existing federal/state privacy protections for biospecimens and associated clinical/demographic data. Mechanism: incorporated human-subject/privacy laws and NIH oversight; no independent new statutory damages remedy

Sec. 501(a), new §404P(f)–(g) · Government Power — Permits multimodal data linkage and requires consent and privacy compliance

``(g) Privacy Protections and Informed Consent.--

Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment

Sec. 501(a), new §404P(g)(1)(A)–(B), (g)(2) · Privacy and Due Process — Requires informed consent or authorized-representative permission and at least existing federal/state privacy protections for biospecimens and associated clinical/demographic data. Mechanism: incorporated human-subject/privacy laws and NIH oversight; no independent new statutory damages remedy

Sec. 501(a), new §404P(f)–(g) · Government Power — Permits multimodal data linkage and requires consent and privacy compliance

``(1) In general.--The Director of NIH shall ensure that any entity collecting data or specimens from any individual through the Biobank Program or conducting any clinical trial using such data or specimens, or in any other way using such data or specimens-- ``(A) collects biospecimens and associated clinical and demographic information only from participants who have given their informed consent in accordance with Federal and State law; and ``(B) protects personal privacy to the extent required by applicable Federal and State law, at minimum.

Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment

Sec. 501(a), new §404P(g)(1)(A)–(B), (g)(2) · Privacy and Due Process — Requires informed consent or authorized-representative permission and at least existing federal/state privacy protections for biospecimens and associated clinical/demographic data. Mechanism: incorporated human-subject/privacy laws and NIH oversight; no independent new statutory damages remedy

Sec. 501(a), new §404P(f)–(g) · Government Power — Permits multimodal data linkage and requires consent and privacy compliance

``(2) Informed consent.--The Director of NIH shall continue to ensure that all biospecimens and associated clinical and other demographic information are collected with the informed consent and authorization of individuals participating in the Biobank Program, or their legally authorized representative, in accordance with the law.

Sec. 501(a), new §404P(h)–(i) · Government Power — Requires annual congressional notification beginning one year after enactment and authorizes $500 million in FY2027 and every later fiscal year, without an express sunset

``(h) Congressional Notification.--Not later than one year after the date of the enactment of this section, and annually thereafter, the Director of NIH shall submit to the appropriate congressional committees a notification on all activities as determined by the advisory board for the Biobank.

Sec. 501(a), new §404P(i) · Economic Freedom — Authorizes $500 million for FY2027 and each subsequent fiscal year, available until expended; no statutory end date. This is an authorization, not an automatic appropriation

Sec. 501(a), new §404P(h)–(i) · Government Power — Requires annual congressional notification beginning one year after enactment and authorizes $500 million in FY2027 and every later fiscal year, without an express sunset

``(i) Authorization of Appropriations.--For purposes of carrying out this section, there is authorized to be appropriated $500,000,000 for fiscal year 2027 and each subsequent fiscal year, to remain available until expended.''.

Sec. 501(b) · Economic Freedom — Requires NIH within 180 days to submit a five-fiscal-year scientific, infrastructure, partnership-financing and budget roadmap. Mechanism: congressional oversight

Sec. 501(b) · Government Power — Requires a five-year implementation and financing roadmap within 180 days

(b) Roadmap.--Not later than 180 days after the date of the enactment of this Act, the Director of NIH shall submit to Congress, in consultation with relevant public and private entities on the advisory board, a roadmap for implementation and augmentation of the Biobank Program established under section 404P of the Public Health Service Act, as added by subsection (a), including scientific priorities, an infrastructure development plan, a public-private partnership financing strategy, and a budget for 5 fiscal years. <all>

Findings source: bill-scores-v2-batch33-findings-2026-11-14.md. Highlights come only from that file; no finding, score, or provision was invented for this page.

What you can do

Contact your U.S. Representative and Senators about this bill.

Find your Representative Contact your Senators

Spot an error on this page? Report it.